{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:07:51Z","timestamp":1782403671913,"version":"3.54.5"},"reference-count":289,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"SECIHTI","award":["1078454"],"award-info":[{"award-number":["1078454"]}]},{"name":"SECIHTI","award":["884808"],"award-info":[{"award-number":["884808"]}]},{"name":"SECIHTI","award":["CBF-2025-G-1656 and SEP-2015-258043"],"award-info":[{"award-number":["CBF-2025-G-1656 and SEP-2015-258043"]}]},{"DOI":"10.13039\/501100006087","name":"Direcci\u00f3n General de Asuntos del Personal Acad\u00e9mico, Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cerebellum"],"DOI":"10.1007\/s12311-026-01981-9","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:34:20Z","timestamp":1775039660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Experimental Models to Study Polyglutamine Spinocerebellar Ataxias: From Mechanisms to Therapeutic Developments"],"prefix":"10.1007","volume":"25","author":[{"given":"Vanessa","family":"Ruiz-Esparza-Palacios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola V.","family":"Borbolla-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranza","family":"Meza-Dorantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Villarreal-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulmaro","family":"Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Maga\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"1981_CR1","doi-asserted-by":"publisher","unstructured":"Klockgether T, Mariotti C, Paulson HL. Spinocerebellar ataxia. Nat Reviews Disease Primers. 2019;5(1). https:\/\/doi.org\/10.1038\/s41572-019-0074-3.","DOI":"10.1038\/s41572-019-0074-3"},{"issue":"3","key":"1981_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000358801","volume":"42","author":"L Ruano","year":"2014","unstructured":"Ruano L, Melo C, Silva MC, Coutinho P. The global epidemiology of hereditary ataxia and spastic paraplegia\u202f: a systematic review of prevalence studies. Neuroepidemiology. 2014;42(3):174\u201383. https:\/\/doi.org\/10.1159\/000358801.","journal-title":"Neuroepidemiology"},{"issue":"2","key":"1981_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00415-018-9076-4","volume":"266","author":"R Sullivan","year":"2019","unstructured":"Sullivan R, Yan W, O\u2019Connor E, Houlden H. Spinocerebellar ataxia\u202f: an update. J Neurol. 2019;266(2):533\u201344. https:\/\/doi.org\/10.1007\/s00415-018-9076-4.","journal-title":"J Neurol"},{"key":"1981_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13071018","author":"FV Borbolla-Jim\u00e9nez","year":"2021","unstructured":"Borbolla-Jim\u00e9nez FV, Prado-Audelo MLD, Cisneros B, Caballero-Flor\u00e1n IH, Leyva-G\u00f3mez G, Maga\u00f1a JJ. New perspectives of gene therapy on polyglutamine spinocerebellar ataxias: From molecular targets to novel nanovectors. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13071018.","journal-title":"Pharmaceutics"},{"key":"1981_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308421","author":"KE Hekman","year":"2015","unstructured":"Hekman KE, Gomez CM. The autosomal dominant spinocerebellar ataxias\u202f:Emerging mechanistic themes suggest pervasive Purkinje cell vulnerability. J Neurol Neurosurg Psychiatry. 2015. https:\/\/doi.org\/10.1136\/jnnp-2014-308421.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1981_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1212\/WNL.0000000000001711","volume":"85","author":"RPPWM Maas","year":"2015","unstructured":"Maas RPPWM, van Gaalen J, Klockgether T, van de Warrenburg BPC. The preclinical stage of spinocerebellar ataxias. Neurology. 2015;85(1):96\u2013103. https:\/\/doi.org\/10.1212\/WNL.0000000000001711.","journal-title":"Neurology"},{"issue":"1","key":"1981_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/nar\/gkr729","volume":"40","author":"WJ Krzyzosiak","year":"2012","unstructured":"Krzyzosiak WJ, Sobczak K, Wojciechowska M, Fiszer A, Mykowska A, Kozlowski P. Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res. 2012;40(1):11\u201326. https:\/\/doi.org\/10.1093\/nar\/gkr729.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"1981_CR8","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1002\/mds.28729","volume":"36","author":"PP Li","year":"2021","unstructured":"Li PP, Moulick R, Feng H, Sun X, Arbez N, Jin J, et al. RNA toxicity and perturbation of rRNA processing in spinocerebellar ataxia type 2. Mov Disord. 2021;36(11):2519\u201329. https:\/\/doi.org\/10.1002\/mds.28729.","journal-title":"Mov Disord"},{"issue":"10","key":"1981_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrn.2017.92","volume":"18","author":"HL Paulson","year":"2017","unstructured":"Paulson HL, Shakkottai VG, Clark HB, Orr HT. Polyglutamine spinocerebellar ataxias \u2014 from genes to potential treatments. Nat Rev Neurosci. 2017;18(10):613\u201326. https:\/\/doi.org\/10.1038\/nrn.2017.92.","journal-title":"Nat Rev Neurosci"},{"key":"1981_CR10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R800065200","author":"JL Marsh","year":"2009","unstructured":"Marsh JL, Lukacsovich T, Thompson LM. Animal models of polyglutamine diseases and therapeutic approaches. J Biol Chem. 2009. https:\/\/doi.org\/10.1074\/jbc.R800065200.","journal-title":"J Biol Chem"},{"key":"1981_CR11","doi-asserted-by":"publisher","unstructured":"Mcintosh CS, Aung-Htut MT, Fletcher S, Wilton SD. Polyglutamine ataxias: From Clinical and Molecular Features to Current Therapeutic Strategies. J Genetic Syndr Gene Therapy. 2017;8(2). https:\/\/doi.org\/10.4172\/2157-7412.1000319.","DOI":"10.4172\/2157-7412.1000319"},{"key":"1981_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-00696-y","author":"RAM Buijsen","year":"2019","unstructured":"Buijsen RAM, Toonen LJA, Gardiner SL, van Roon-Mom WMC, Springer New York LLC. Genetics, mechanisms, and therapeutic progress in polyglutamine spinocerebellar ataxias. Neurotherapeutics. 2019. https:\/\/doi.org\/10.1007\/s13311-018-00696-y.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"1981_CR13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/jmcb\/mjq005","volume":"2","author":"T Takahashi","year":"2010","unstructured":"Takahashi T, Katada S, Onodera O. Polyglutamine diseases: where does toxicity come from? What is toxicity? Where are we going? J Mol Cell Biol. 2010;2(4):180\u201391. https:\/\/doi.org\/10.1093\/jmcb\/mjq005.","journal-title":"J Mol Cell Biol"},{"key":"1981_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neulet.2018.02.004","volume":"688","author":"M Huang","year":"2019","unstructured":"Huang M, Verbeek DS. Why do so many genetic insults lead to Purkinje Cell degeneration and spinocerebellar ataxia? Neurosci Lett. 2019;688:49\u201357. https:\/\/doi.org\/10.1016\/j.neulet.2018.02.004.","journal-title":"Neurosci Lett"},{"key":"1981_CR15","doi-asserted-by":"crossref","unstructured":"Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. (2004). Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Retrieved from www.nature.com\/nature.","DOI":"10.1038\/nature02998"},{"key":"1981_CR16","doi-asserted-by":"publisher","unstructured":"Marcelo A, Koppenol R, de Almeida LP, Matos CA, N\u00f3brega C. (2021, June 1). Stress granules, RNA-binding proteins and polyglutamine diseases: too much aggregation? Cell Death and Disease. Springer Nature. https:\/\/doi.org\/10.1038\/s41419-021-03873-8","DOI":"10.1038\/s41419-021-03873-8"},{"key":"1981_CR17","unstructured":"Scholarship W, Di Gregorio SE, Duennwald M, Gregorio D. (2021). Protein misfolding toxicity and inclusion formation in cellular models of neurodegeneration. Retrieved from https:\/\/ir.lib.uwo.ca\/etdRepository.7775.https:\/\/ir.lib.uwo.ca\/etd\/7775"},{"key":"1981_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.02.003","author":"F Saudou","year":"2016","unstructured":"Saudou F, Humbert S. The Biology of Huntingtin. Neuron. 2016. https:\/\/doi.org\/10.1016\/j.neuron.2016.02.003.","journal-title":"Neuron"},{"key":"1981_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.642623","author":"M Gonzalez-Garcia","year":"2021","unstructured":"Gonzalez-Garcia M, Fusco G, De Simone A. Membrane interactions and toxicity by misfolded protein oligomers. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2021.642623.","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"1981_CR20","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1242\/jcs.180737","volume":"129","author":"PR Angelova","year":"2016","unstructured":"Angelova PR, Ludtmann MHR, Horrocks MH, Negoda A, Cremades N, Klenerman D, Abramov AY. Ca2\u2009+\u2009is a key factor in \u03b1-synuclein-induced neurotoxicity. J Cell Sci. 2016;129(9):1792\u2013801. https:\/\/doi.org\/10.1242\/jcs.180737.","journal-title":"J Cell Sci"},{"key":"1981_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/2105607","volume":"2019","author":"G Cenini","year":"2019","unstructured":"Cenini G, Lloret A, Cascella R. Oxidative stress in neurodegenerative diseases: from a mitochondrial point of view. Oxid Med Cell Longev. 2019;2019:1\u201318. https:\/\/doi.org\/10.1155\/2019\/2105607.","journal-title":"Oxid Med Cell Longev"},{"issue":"10","key":"1981_CR22","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/glia.22548","volume":"61","author":"AN Shrivastava","year":"2013","unstructured":"Shrivastava AN, Kowalewski JM, Renner M, Bousset L, Koulakoff A, Melki R, et al. \u03b2-amyloid and ATP-induced diffusional trapping of astrocyte and neuronal metabotropic glutamate type-5 receptors. Glia. 2013;61(10):1673\u201386. https:\/\/doi.org\/10.1002\/glia.22548.","journal-title":"Glia"},{"issue":"4","key":"1981_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/15476286.2015.1020271","volume":"12","author":"LL Chen","year":"2015","unstructured":"Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12(4):381\u20138. https:\/\/doi.org\/10.1080\/15476286.2015.1020271.","journal-title":"RNA Biol"},{"key":"1981_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cells12232735","author":"FV Borbolla-Jim\u00e9nez","year":"2023","unstructured":"Borbolla-Jim\u00e9nez FV, Garc\u00eda-Aguirre IA, Del Prado-Audelo ML, Hern\u00e1ndez-Hern\u00e1ndez O, Cisneros B, Leyva-G\u00f3mez G, et al. Development of a polymeric pharmacological nanocarrier system as a potential therapy for spinocerebellar ataxia type 7. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12232735.","journal-title":"Cells"},{"key":"1981_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2011\/265084","volume":"2011","author":"HA Popiel","year":"2011","unstructured":"Popiel HA, Burke JR, Strittmatter WJ, Oishi S, Fujii N, Takeuchi T, et al. The aggregation inhibitor peptide QBP1 as a therapeutic molecule for the polyglutamine neurodegenerative diseases. J Amino Acids. 2011;2011:1\u201310. https:\/\/doi.org\/10.4061\/2011\/265084.","journal-title":"J Amino Acids"},{"key":"1981_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci7100128","author":"T Takeuchi","year":"2017","unstructured":"Takeuchi T, Nagai Y. Protein misfolding and aggregation as a therapeutic target for polyglutamine diseases. Brain Sci. 2017. https:\/\/doi.org\/10.3390\/brainsci7100128.","journal-title":"Brain Sci"},{"issue":"6","key":"1981_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06812-5","volume":"15","author":"RG Costa","year":"2024","unstructured":"Costa RG, Concei\u00e7\u00e3o A, Matos CA, N\u00f3brega C. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease. Cell Death & Disease. 2024;15(6):415. https:\/\/doi.org\/10.1038\/s41419-024-06812-5.","journal-title":"Cell Death & Disease"},{"issue":"9","key":"1981_CR28","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.stem.2021.04.004","volume":"28","author":"J Mertens","year":"2021","unstructured":"Mertens J, Herdy JR, Traxler L, Schafer ST, Schlachetzki JCM, B\u00f6hnke L, et al. Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer\u2019s patients. Cell Stem Cell. 2021;28(9):1533-1548.e6. https:\/\/doi.org\/10.1016\/j.stem.2021.04.004.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"1981_CR29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.stem.2012.04.027","volume":"11","author":"The HD iPSC Consortium","year":"2012","unstructured":"The HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington\u2019s disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell. 2012;11(2):264\u201378. https:\/\/doi.org\/10.1016\/j.stem.2012.04.027.","journal-title":"Cell Stem Cell"},{"issue":"5459","key":"1981_CR30","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1126\/science.287.5459.1837","volume":"287","author":"P Kazemi-Esfarjani","year":"2000","unstructured":"Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Sci (New York N Y). 2000;287(5459):1837\u201340. https:\/\/doi.org\/10.1126\/science.287.5459.1837.","journal-title":"Sci (New York N Y)"},{"issue":"11","key":"1981_CR31","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.1073\/pnas.100107297","volume":"97","author":"SH Satyal","year":"2000","unstructured":"Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, Kramer JM, et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci USA. 2000;97(11):5750\u20135. https:\/\/doi.org\/10.1073\/pnas.100107297.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1981_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S0076-6879(06)12016-9","volume":"412","author":"HR Brignull","year":"2006","unstructured":"Brignull HR, Morley JF, Garcia SM, Morimoto RI. Modeling polyglutamine pathogenesis in C. elegans. Methods Enzymol. 2006;412:256\u201382. https:\/\/doi.org\/10.1016\/S0076-6879(06)12016-9.","journal-title":"Methods Enzymol"},{"issue":"16","key":"1981_CR33","doi-asserted-by":"publisher","first-page":"10417","DOI":"10.1073\/pnas.152161099","volume":"99","author":"JF Morley","year":"2002","unstructured":"Morley JF, Brignull HR, Weyers JJ, Morimoto RI. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci. 2002;99(16):10417\u201322. https:\/\/doi.org\/10.1073\/pnas.152161099.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"1981_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/hmg\/dds427","volume":"22","author":"ST Hansen","year":"2013","unstructured":"Hansen ST, Meera P, Otis TS, Pulst SM. Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2. Hum Mol Genet. 2013;22(2):271\u201383. https:\/\/doi.org\/10.1093\/hmg\/dds427.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"1981_CR35","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s12311-010-0182-9","volume":"11","author":"A Kasumu","year":"2012","unstructured":"Kasumu A, Bezprozvanny I. Deranged calcium signaling in purkinje cells and pathogenesis in spinocerebellar ataxia 2 (SCA2) and other ataxias. Cerebellum. 2012;11(3):630\u20139. https:\/\/doi.org\/10.1007\/s12311-010-0182-9.","journal-title":"Cerebellum"},{"issue":"4","key":"1981_CR36","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/ana.27032","volume":"96","author":"TH van Prooije","year":"2024","unstructured":"van Prooije TH, Kapteijns KCJ, van Asten JJA, IntHout J, Verbeek MM, Scheenen TWJ, et al. Multimodal, longitudinal profiling of SCA1 identifies predictors of disease severity and progression. Ann Neurol. 2024;96(4):774\u201387. https:\/\/doi.org\/10.1002\/ana.27032.","journal-title":"Ann Neurol"},{"issue":"2","key":"1981_CR37","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/ana.26824","volume":"95","author":"J Faber","year":"2024","unstructured":"Faber J, Berger M, Wilke C, Hubener-Schmid J, Schaprian T, Santana MM, et al. Stage-dependent biomarker changes in spinocerebellar ataxia type 3. Ann Neurol. 2024;95(2):400\u20136. https:\/\/doi.org\/10.1002\/ana.26824.","journal-title":"Ann Neurol"},{"key":"1981_CR38","doi-asserted-by":"publisher","unstructured":"Tezenas du Montcel S, Petit E, Olubajo T, Faber J, Lallemant-Dudek P, Bushara K, Ashizawa T. Baseline Clinical and Blood Biomarkers in Patients With Preataxic and Early-Stage Disease Spinocerebellar Ataxia 1 and 3. Neurology. 2023;100(17). https:\/\/doi.org\/10.1212\/WNL.0000000000207088.","DOI":"10.1212\/WNL.0000000000207088"},{"key":"1981_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105311","volume":"153","author":"G Coarelli","year":"2021","unstructured":"Coarelli G, Darios F, Petit E, Dorgham K, Adanyeguh I, Petit E, et al. Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia. Neurobiol Dis. 2021;153:105311. https:\/\/doi.org\/10.1016\/j.nbd.2021.105311.","journal-title":"Neurobiol Dis"},{"key":"1981_CR40","doi-asserted-by":"publisher","unstructured":"Coarelli G, Dubec-Fleury C, Petit E, Sayah S, Fischer C, Nassisi M, Durr A. Longitudinal Changes of Clinical, Imaging, and Fluid Biomarkers in Preataxic and Early Ataxic Spinocerebellar Ataxia Type 2 and 7 Carriers. Neurology. 2024;103(5). https:\/\/doi.org\/10.1212\/WNL.0000000000209749.","DOI":"10.1212\/WNL.0000000000209749"},{"issue":"1","key":"1981_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/life13010023","volume":"13","author":"R Su\u00e1rez-S\u00e1nchez","year":"2022","unstructured":"Su\u00e1rez-S\u00e1nchez R, \u00c1vila-Avil\u00e9s RD, Hern\u00e1ndez-Hern\u00e1ndez JM, S\u00e1nchez-Celis D, Azotla-Vilchis CN, G\u00f3mez-Mac\u00edas ER, et al. RNA foci formation in a retinal glial model for spinocerebellar ataxia type 7. Life. 2022;13(1):23. https:\/\/doi.org\/10.3390\/life13010023.","journal-title":"Life"},{"key":"1981_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00571","author":"A Niewiadomska-Cimicka","year":"2020","unstructured":"Niewiadomska-Cimicka A, Hache A, Trottier Y. Gene deregulation and underlying mechanisms in spinocerebellar ataxias with polyglutamine expansion. Front Neurosci. 2020. https:\/\/doi.org\/10.3389\/fnins.2020.00571.","journal-title":"Front Neurosci"},{"issue":"12","key":"1981_CR43","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00439-023-02607-4","volume":"142","author":"D Fel\u00edcio","year":"2023","unstructured":"Fel\u00edcio D, du M\u00e9rac TR, Amorim A, Martins S. Functional implications of paralog genes in polyglutamine spinocerebellar ataxias. Hum Genet. 2023;142(12):1651\u201376. https:\/\/doi.org\/10.1007\/s00439-023-02607-4.","journal-title":"Hum Genet"},{"issue":"2","key":"1981_CR44","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.neulet.2009.03.004","volume":"454","author":"WH Chang","year":"2009","unstructured":"Chang WH, Tien CL, Chen TJ, Nukina N, Hsieh M. Decreased protein synthesis of Hsp27 associated with cellular toxicity in a cell model of Machado-Joseph disease. Neurosci Lett. 2009;454(2):152\u20136. https:\/\/doi.org\/10.1016\/j.neulet.2009.03.004.","journal-title":"Neurosci Lett"},{"key":"1981_CR45","doi-asserted-by":"crossref","unstructured":"Emamian, E. S., Kaytor, M. D., Duvick, L. A., Zu, T., Tousey, S. K., Zoghbi, H. Y.,\u2026 Orr, H. T. (2003). Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice PDF. Neuron (Vol. 38).","DOI":"10.1016\/S0896-6273(03)00258-7"},{"issue":"10","key":"1981_CR46","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/jnr.24474","volume":"97","author":"M Hsieh","year":"2019","unstructured":"Hsieh M, Hsieh BY, Ma CY, Li YT, Liu CS, Lo CM. Protective roles of carbonic anhydrase 8 in Machado\u2013Joseph disease. J Neurosci Res. 2019;97(10):1278\u201397. https:\/\/doi.org\/10.1002\/jnr.24474.","journal-title":"J Neurosci Res"},{"issue":"4","key":"1981_CR47","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s12031-021-01944-1","volume":"72","author":"H Huang","year":"2022","unstructured":"Huang H, Toker N, Burr E, Okoro J, Moog M, Hearing C, et al. Intercellular propagation and aggregate seeding of mutant Ataxin-1. J Mol Neurosci. 2022;72(4):708\u201318. https:\/\/doi.org\/10.1007\/s12031-021-01944-1.","journal-title":"J Mol Neurosci"},{"issue":"1","key":"1981_CR48","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.expneurol.2006.03.029","volume":"201","author":"M Jeub","year":"2006","unstructured":"Jeub M, Herbst M, Spauschus A, Fleischer H, Klockgether T, Wuellner U, Evert BO. Potassium channel dysfunction and depolarized resting membrane potential in a cell model of SCA3. Exp Neurol. 2006;201(1):182\u201392. https:\/\/doi.org\/10.1016\/j.expneurol.2006.03.029.","journal-title":"Exp Neurol"},{"issue":"6","key":"1981_CR49","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.bbadis.2012.01.016","volume":"1822","author":"L Mapelli","year":"2012","unstructured":"Mapelli L, Canale C, Pesci D, Averaimo S, Guizzardi F, Fortunati V, et al. Toxic effects of expanded ataxin-1 involve mechanical instability of the nuclear membrane. Biochim Biophys Acta Mol Basis Dis. 2012;1822(6):906\u201317. https:\/\/doi.org\/10.1016\/j.bbadis.2012.01.016.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"1981_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2202-13-86","volume":"13","author":"A Ajayi","year":"2012","unstructured":"Ajayi A, Yu X, Lindberg S, Langel \u00dc, Str\u00f6m A-L. Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCA7) model. BMC Neurosci. 2012;13(1):1\u201314.","journal-title":"BMC Neurosci"},{"key":"1981_CR51","doi-asserted-by":"publisher","unstructured":"Laidou S, Alanis-Lobato G, Pribyl J, Rask\u00f3 T, Tichy B, Mikulasek K, Petrakis S. Nuclear inclusions of pathogenic ataxin-1 induce oxidative stress and perturb the protein synthesis machinery. Redox Biol. 2020;32. https:\/\/doi.org\/10.1016\/j.redox.2020.101458.","DOI":"10.1016\/j.redox.2020.101458"},{"key":"1981_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2020.103584","author":"F Niss","year":"2021","unstructured":"Niss F, Zaidi W, Hallberg E, Str\u00f6m AL. Polyglutamine expanded Ataxin-7 induces DNA damage and alters FUS localization and function. Mol Cell Neurosci. 2021. https:\/\/doi.org\/10.1016\/j.mcn.2020.103584.","journal-title":"Mol Cell Neurosci"},{"key":"1981_CR53","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12031-012-9722-8","volume":"47","author":"X Yu","year":"2012","unstructured":"Yu X, Ajayi A, Rao Boga N, Str\u00f6m A-L. Differential Degradation of Full-length and Cleaved Ataxin-7 Fragments in a Novel Stable Inducible SCA7 Model. J Mol Neurosci. 2012;47:219\u201333.","journal-title":"J Mol Neurosci"},{"issue":"21","key":"1981_CR54","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.1158\/0008-5472.CAN-15-1626","volume":"75","author":"IA Chatzispyrou","year":"2015","unstructured":"Chatzispyrou IA, Held NM, Mouchiroud L, Auwerx J, Houtkooper RH. Tetracycline antibiotics impair mitochondrial function and its experimental use confounds research. Cancer Res. 2015;75(21):4446\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1626.","journal-title":"Cancer Res"},{"issue":"22","key":"1981_CR55","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1089\/scd.2017.0085","volume":"26","author":"C Bavassano","year":"2017","unstructured":"Bavassano C, Eigentler A, Stanika R, Obermair GJ, Boesch S, Dechant G, Nat R. Bicistronic CACNA1A Gene Expression in Neurons Derived from Spinocerebellar Ataxia Type 6 Patient-Induced Pluripotent Stem Cells. Stem Cells Dev. 2017;26(22):1612\u201325. https:\/\/doi.org\/10.1089\/scd.2017.0085.","journal-title":"Stem Cells Dev"},{"key":"1981_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247434","author":"RJ Burman","year":"2021","unstructured":"Burman RJ, Watson LM, Smith DC, Raimondo JV, Ballo R, Scholefield J, et al. Molecular and electrophysiological features of spinocerebellar ataxia type seven in induced pluripotent stem cells. PLoS One. 2021. https:\/\/doi.org\/10.1371\/journal.pone.0247434.","journal-title":"PLoS One"},{"key":"1981_CR57","doi-asserted-by":"publisher","unstructured":"Chuang CY, Yang CC, Soong BW, Yu CY, Chen SH, Huang HP, Kuo HC. Modeling spinocerebellar ataxias 2 and 3 with iPSCs reveals a role for glutamate in disease pathology. Sci Rep. 2019;9(1). https:\/\/doi.org\/10.1038\/s41598-018-37774-2.","DOI":"10.1038\/s41598-018-37774-2"},{"issue":"2","key":"1981_CR58","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.scr.2016.07.004","volume":"17","author":"SK Hansen","year":"2016","unstructured":"Hansen SK, Stummann TC, Borland H, Hasholt LF, T\u00fcmer Z, Nielsen JE, et al. Induced pluripotent stem cell - derived neurons for the study of spinocerebellar ataxia type 3. Stem Cell Res. 2016;17(2):306\u201317. https:\/\/doi.org\/10.1016\/j.scr.2016.07.004.","journal-title":"Stem Cell Res"},{"key":"1981_CR59","doi-asserted-by":"publisher","unstructured":"He, L., Wang, S., Peng, L., Zhao, H., Li, S., Han, X., \u2026 Jiang, H. (2021). CRISPR\/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells. Translational Psychiatry, 11(1). https:\/\/doi.org\/10.1038\/s41398-021-01605-2.","DOI":"10.1038\/s41398-021-01605-2."},{"issue":"6","key":"1981_CR60","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.celrep.2016.10.026","volume":"17","author":"Y Ishida","year":"2016","unstructured":"Ishida Y, Kawakami H, Kitajima H, Nishiyama A, Sasai Y, Inoue H, Muguruma K. Vulnerability of Purkinje Cells Generated from Spinocerebellar Ataxia Type 6 Patient-Derived iPSCs. Cell Rep. 2016;17(6):1482\u201390. https:\/\/doi.org\/10.1016\/j.celrep.2016.10.026.","journal-title":"Cell Rep"},{"key":"1981_CR61","doi-asserted-by":"publisher","unstructured":"Marcelo, A., Afonso, I. T., Afonso-Reis, R., Brito, D. V. C., Costa, R. G., Rosa,A., \u2026 N\u00f3brega, C. (2021). Autophagy in Spinocerebellar ataxia type 2, a dysregulated pathway,and a target for therapy. Cell Death and Disease, 12(12). https:\/\/doi.org\/10.1038\/s41419-021-04404-1.","DOI":"10.1038\/s41419-021-04404-1."},{"issue":"5","key":"1981_CR62","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2019.01.028","volume":"26","author":"JM Ward","year":"2019","unstructured":"Ward JM, Stoyas CA, Switonski PM, Ichou F, Fan W, Collins B, et al. Metabolic and organelle morphology defects in mice and human patients define spinocerebellar ataxia type 7 as a mitochondrial disease. Cell Rep. 2019;26(5):1189-1202.e6. https:\/\/doi.org\/10.1016\/j.celrep.2019.01.028.","journal-title":"Cell Rep"},{"issue":"2","key":"1981_CR63","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12031-012-9930-2","volume":"51","author":"G Xia","year":"2013","unstructured":"Xia G, Santostefano K, Hamazaki T, Liu J, Subramony SH, Terada N, Ashizawa T. Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro. J Mol Neurosci. 2013;51(2):237\u201348. https:\/\/doi.org\/10.1007\/s12031-012-9930-2.","journal-title":"J Mol Neurosci"},{"key":"1981_CR64","doi-asserted-by":"publisher","unstructured":"Slanzi A, Iannoto G, Rossi B, Zenaro E, Constantin G. May 13). In vitro Models of Neurodegenerative Diseases. Frontiers in Cell and Developmental Biology. Frontiers Media S.A; 2020. https:\/\/doi.org\/10.3389\/fcell.2020.00328.","DOI":"10.3389\/fcell.2020.00328"},{"issue":"6","key":"1981_CR65","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s11011-022-00994-7","volume":"37","author":"G-Y Lin","year":"2022","unstructured":"Lin G-Y, Ma C-Y, Kuo L-C, Hsieh BY, Wang H, Liu C-S, Hsieh M. Altered glucose metabolism and its association with carbonic anhydrase 8 in Machado-Joseph Disease. Metab Brain Dis. 2022;37(6):2103\u201320. https:\/\/doi.org\/10.1007\/s11011-022-00994-7.","journal-title":"Metab Brain Dis"},{"key":"1981_CR66","doi-asserted-by":"publisher","unstructured":"Harmuth T, Prell-Schicker C, Weber JJ, Gellerich F, Funke C, Drie\u00dfen S, H\u00fcbener-Schmid J. Mitochondrial Morphology, Function and Homeostasis Are Impaired by Expression of an N-terminal Calpain Cleavage Fragment of Ataxin-3. Front Mol Neurosci. 2018;11. https:\/\/doi.org\/10.3389\/fnmol.2018.00368.","DOI":"10.3389\/fnmol.2018.00368"},{"key":"1981_CR67","doi-asserted-by":"publisher","unstructured":"Harmuth, T., Weber, J. J., Zimmer, A. J., Sowa, A. S., Schmidt, J., Fitzgerald, J.C., \u2026 H\u00fcbener-schmid, J. (2022). Mitochondrial Dysfunction in Spinocerebellar Ataxia Type 3 Is Linked to VDAC1 Deubiquitination. International Journal of Molecular Sciences, 23(11). https:\/\/doi.org\/10.3390\/ijms23115933.","DOI":"10.3390\/ijms23115933."},{"issue":"12","key":"1981_CR68","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/nn2011","volume":"10","author":"MJ Friedman","year":"2007","unstructured":"Friedman MJ, Shah AG, Fang ZH, Ward EG, Warren ST, Li S, et al. Polyglutamine domain modulates the TBP-TFIIB interaction: Implications for its normal function and neurodegeneration. Nat Neurosci. 2007;10(12):1519\u201328. https:\/\/doi.org\/10.1038\/nn2011.","journal-title":"Nat Neurosci"},{"key":"1981_CR69","doi-asserted-by":"publisher","unstructured":"Ghosh T, Pandey N, Maitra A, Brahmachari SK, Pillai B. A role for voltage-dependent anion channel Vdac1 in polyglutamine-mediated neuronal cell death. PLoS ONE. 2007;2(11). https:\/\/doi.org\/10.1371\/journal.pone.0001170.","DOI":"10.1371\/journal.pone.0001170"},{"key":"1981_CR70","doi-asserted-by":"publisher","unstructured":"Lee LC, Chen CM, Wang HC, Hsieh HH, Chiu IS, Su MT, Lin JY. Role of the CCAAT-binding protein NFY in SCA17 pathogenesis. PLoS ONE. 2012;7(4). https:\/\/doi.org\/10.1371\/journal.pone.0035302.","DOI":"10.1371\/journal.pone.0035302"},{"issue":"2","key":"1981_CR71","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1083\/jcb.201105092","volume":"197","author":"HT Orr","year":"2012","unstructured":"Orr HT. Cell biology of spinocerebellar ataxia. J Cell Biol. 2012;197(2):167\u201377. https:\/\/doi.org\/10.1083\/jcb.201105092.","journal-title":"J Cell Biol"},{"key":"1981_CR72","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1146\/annurev.neuro.29.051605.113042","volume":"30","author":"HT Orr","year":"2007","unstructured":"Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci. 2007;30:575\u2013623. https:\/\/doi.org\/10.1146\/annurev.neuro.29.051605.113042.","journal-title":"Annu Rev Neurosci"},{"key":"1981_CR73","doi-asserted-by":"publisher","unstructured":"Li J, Fraenkel E. Phenotyping Neurodegeneration in Human iPSCs. Annual Rev Biomedical Data Sci Annu Rev Biomed Data Sci. 2025;2021(2021). https:\/\/doi.org\/10.1146\/annurev-biodatasci-092820.","DOI":"10.1146\/annurev-biodatasci-092820"},{"issue":"6","key":"1981_CR74","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.stem.2015.09.001","volume":"17","author":"J Mertens","year":"2015","unstructured":"Mertens J, Paquola ACM, Ku M, Hatch E, B\u00f6hnke L, Ladjevardi S, et al. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell. 2015;17(6):705\u201318. https:\/\/doi.org\/10.1016\/j.stem.2015.09.001.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"1981_CR75","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.neuron.2021.03.022","volume":"109","author":"DM Ramos","year":"2021","unstructured":"Ramos DM, Skarnes WC, Singleton AB, Cookson MR, Ward ME. Tackling neurodegenerative diseases with genomic engineering: a new stem cell initiative from the NIH. Neuron. 2021;109(7):1080\u20133. https:\/\/doi.org\/10.1016\/j.neuron.2021.03.022.","journal-title":"Neuron"},{"issue":"5","key":"1981_CR76","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.stemcr.2017.09.024","volume":"9","author":"K Fujimori","year":"2017","unstructured":"Fujimori K, Matsumoto T, Kisa F, Hattori N, Okano H, Akamatsu W. Escape from pluripotency via inhibition of TGF-\u03b2\/BMP and activation of Wnt signaling accelerates differentiation and aging in hPSC progeny cells. Stem Cell Rep. 2017;9(5):1675\u201391. https:\/\/doi.org\/10.1016\/j.stemcr.2017.09.024.","journal-title":"Stem Cell Rep"},{"issue":"2","key":"1981_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10020421","volume":"10","author":"A Quelle-Regaldie","year":"2021","unstructured":"Quelle-Regaldie A, Sobrido-Came\u00e1n D, Barreiro-Iglesias A, Sobrido MJ, S\u00e1nchez L. Zebrafish models of autosomal dominant ataxias. Cells. 2021;10(2):1\u201321. https:\/\/doi.org\/10.3390\/cells10020421.","journal-title":"Cells"},{"key":"1981_CR78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.expneurol.2015.08.002","volume":"274","author":"Z Xu","year":"2015","unstructured":"Xu Z, Joel Tito A, Rui Y-N, Zhang S. Studying polyglutamine diseases in Drosophila. Exp Neurol. 2015;274:25\u201341. https:\/\/doi.org\/10.1016\/j.expneurol.2015.08.002.","journal-title":"Exp Neurol"},{"key":"1981_CR79","doi-asserted-by":"publisher","unstructured":"Sotiriou A, Ploumi C, Charmpilas N, Tavernarakis N. (2024). Assessing polyglutamine tract aggregation in the nematode Caenorhabditis elegans (pp. 1\u201315). https:\/\/doi.org\/10.1016\/bs.mcb.2022.09.003","DOI":"10.1016\/bs.mcb.2022.09.003"},{"issue":"3","key":"1981_CR80","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s12311-021-01311-1","volume":"21","author":"J Cendelin","year":"2022","unstructured":"Cendelin J, Cvetanovic M, Gandelman M, Hirai H, Orr HT, Pulst SM, et al. Consensus paper: strengths and weaknesses of animal models of spinocerebellar ataxias and their clinical implications. Cerebellum. 2022;21(3):452\u201381. https:\/\/doi.org\/10.1007\/s12311-021-01311-1.","journal-title":"Cerebellum"},{"key":"1981_CR81","doi-asserted-by":"publisher","unstructured":"Wu Y, Chen Y, Yu X, Zhang M, Li Z. (2024). Towards Understanding Neurodegenerative Diseases: Insights from Caenorhabditis elegans. International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute (MDPI). https:\/\/doi.org\/10.3390\/ijms25010443","DOI":"10.3390\/ijms25010443"},{"key":"1981_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2019.12.011","author":"M Markaki","year":"2020","unstructured":"Markaki M, Tavernarakis N. Caenorhabditis elegans as a model system for human diseases. Curr Opin Biotechnol. 2020. https:\/\/doi.org\/10.1016\/j.copbio.2019.12.011.","journal-title":"Curr Opin Biotechnol"},{"key":"1981_CR83","doi-asserted-by":"publisher","unstructured":"Jalles, A., Vieira, C., Pereira-Sousa, J., Vilasboas-Campos, D., Mota, A. F., Vasconcelos,S., \u2026 Teixeira-Castro, A. (2022). Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine D2 and Serotonin 1A and 2A Receptors in C. elegans. Biomedicines, 10(2). https:\/\/doi.org\/10.3390\/biomedicines10020370.","DOI":"10.3390\/biomedicines10020370."},{"key":"1981_CR84","doi-asserted-by":"publisher","unstructured":"Figueiredo, F., S\u00e1rk\u00e1ny, Z., Silva, A., Vilasboas-Campos, D., Maciel, P., Teixeira-Castro,A., \u2026 Macedo-Ribeiro, S. (2023). Drug repurposing of dopaminergic drugs to inhibit ataxin-3 aggregation. Biomedicine and Pharmacotherapy, 165. https:\/\/doi.org\/10.1016\/j.biopha.2023.115258.","DOI":"10.1016\/j.biopha.2023.115258."},{"key":"1981_CR85","doi-asserted-by":"publisher","unstructured":"Farina, F., Lambert, E., Commeau, L., Lejeune, F. X., Roudier, N., Fonte, C., \u2026 Neri,C. (2017). The stress response factor daf-16 \/FOXO is required for multiple compound families to prolong the function of neurons with Huntington\u2019s disease. Scientific Reports, 7(1). https:\/\/doi.org\/10.1038\/s41598-017-04256-w.","DOI":"10.1038\/s41598-017-04256-w."},{"key":"1981_CR86","doi-asserted-by":"publisher","unstructured":"Chen, X., McCuef, H. V., Wong, S. Q., Kashyap, S. S., Kraemer, B. C., Barclay, J.W., \u2026 Morgan, A. (2015). Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16\/FOXO target gene expression. Molecular Neurodegeneration, 10(1). https:\/\/doi.org\/10.1186\/s13024-015-0046-3.","DOI":"10.1186\/s13024-015-0046-3."},{"key":"1981_CR87","doi-asserted-by":"publisher","unstructured":"Lejeune, F. X., Mesrob, L., Parmentier, F., Bicep, C., Vazquez-Manrique, R. P., Parker,J. A., \u2026 Neri, C. (2012). Large-scale functional RNAi screen in C. elegans identifies genes that regulate the dysfunction of mutant polyglutamine neurons. BMC Genomics, 13(1). https:\/\/doi.org\/10.1186\/1471-2164-13-91.","DOI":"10.1186\/1471-2164-13-91."},{"key":"1981_CR88","doi-asserted-by":"publisher","unstructured":"G\u00f3mez-Escribano, A. P., Mora\u2010Mart\u00ednez, C., Roca, M., Walker, D. S., Panadero, J.,Sequedo, M. D., \u2026 V\u00e1zquez\u2010Manrique, R. P. (2023). Changes in lipid metabolism driven by steroid signalling modulate proteostasis in C. elegans. EMBO reports, 24(6). https:\/\/doi.org\/10.15252\/embr.202255556.","DOI":"10.15252\/embr.202255556."},{"key":"1981_CR89","doi-asserted-by":"publisher","unstructured":"Victor Atoki, A., Aja, P. M., Shinkafi, T. S., Ondari, E. N., Adeniyi, A. I., Fasogbon,I. V., \u2026 Akin-Adewumi, A. (2025). Exploring the versatility of Drosophila melanogaster as a model organism in biomedical research: a comprehensive review. Fly. Taylor and Francis Ltd. https:\/\/doi.org\/10.1080\/19336934.2024.2420453.","DOI":"10.1080\/19336934.2024.2420453."},{"key":"1981_CR90","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2019.1569624","author":"K Papanikolopoulou","year":"2019","unstructured":"Papanikolopoulou K, Mudher A, Skoulakis E. An assessment of the translational relevance of Drosophila in drug discovery. Expert Opin Drug Discov. 2019. https:\/\/doi.org\/10.1080\/17460441.2019.1569624.","journal-title":"Expert Opin Drug Discov"},{"issue":"2","key":"1981_CR91","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.bbrc.2017.12.021","volume":"495","author":"M Kim","year":"2018","unstructured":"Kim M, Subramanian M, Cho Y-H, Kim G-H, Lee E, Park J-J. Short-term exposure to dim light at night disrupts rhythmic behaviors and causes neurodegeneration in fly models of tauopathy and Alzheimer\u2019s disease. Biochem Biophys Res Commun. 2018;495(2):1722\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2017.12.021.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"1981_CR92","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.bbadis.2017.07.013","volume":"1863","author":"D Molina-Mateo","year":"2017","unstructured":"Molina-Mateo D, Fuenzalida-Uribe N, Hidalgo S, Molina-Fern\u00e1ndez C, Abarca J, Z\u00e1rate RV, et al. Characterization of a presymptomatic stage in a Drosophila Parkinson\u2019s disease model: unveiling dopaminergic compensatory mechanisms. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2017;1863(11):2882\u201390. https:\/\/doi.org\/10.1016\/j.bbadis.2017.07.013.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"1981_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093055","author":"H Bolus","year":"2020","unstructured":"Bolus H, Crocker K, Boekhoff-Falk G, Chtarbanova S. Modeling neurodegenerative disorders in Drosophila melanogaster. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21093055.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1981_CR94","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1093\/hmg\/ddr124","volume":"20","author":"PS Estes","year":"2011","unstructured":"Estes PS, Boehringer A, Zwick R, Tang JE, Grigsby B, Zarnescu DC. Wild-type and A315T mutant TDP-43 exert differential neurotoxicity in a Drosophila model of ALS. Hum Mol Genet. 2011;20(12):2308\u201321. https:\/\/doi.org\/10.1093\/hmg\/ddr124.","journal-title":"Hum Mol Genet"},{"issue":"7567","key":"1981_CR95","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature14974","volume":"525","author":"BD Freibaum","year":"2015","unstructured":"Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee K-H, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525(7567):129\u201333. https:\/\/doi.org\/10.1038\/nature14974.","journal-title":"Nature"},{"key":"1981_CR96","doi-asserted-by":"publisher","unstructured":"Park, J., Al-Ramahi, I., Tan, Q., Mollema, N., Diaz-Garcia, J. R., Gallego-Flores,T., \u2026 Zoghbi, H. Y. (2013). Genetic screens reveal RAS\/MAPK\/MSK1 modulate ataxin 1 protein levels and toxicity in SCA1. Nature, 498(7454), 325\u2013331. https:\/\/doi.org\/10.1038\/nature12204.","DOI":"10.1038\/nature12204."},{"issue":"8","key":"1981_CR97","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/hmg\/ddx039","volume":"26","author":"JR Sutton","year":"2017","unstructured":"Sutton JR, Blount JR, Libohova K, Tsou WL, Joshi GS, Paulson HL, et al. Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in drosophila models of spinocerebellar ataxia type 3. Hum Mol Genet. 2017;26(8):1419\u201331. https:\/\/doi.org\/10.1093\/hmg\/ddx039.","journal-title":"Hum Mol Genet"},{"key":"1981_CR98","doi-asserted-by":"publisher","unstructured":"Sujkowski, A., Ranxhi, B., Bangash, Z. R., Chbihi, Z. M., Prifti, M. V., Qadri, Z.,\u2026 Tsou, W. L. (2024). Progressive degeneration in a new Drosophila model of spinocerebellar ataxia type 7. Scientific Reports, 14(1). https:\/\/doi.org\/10.1038\/s41598-024-65172-4.","DOI":"10.1038\/s41598-024-65172-4."},{"key":"1981_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen","author":"J Bilen","year":"2007","unstructured":"Bilen J, Bonini NM. Genome-Wide Screen for Modifiers of Ataxin-3 Neurodegeneration in Drosophila. PLoS Genet. 2007. https:\/\/doi.org\/10.1371\/journal.pgen.","journal-title":"PLoS Genet"},{"key":"1981_CR100","doi-asserted-by":"publisher","unstructured":"Lee, W. S., Al-Ramahi, I., Jeong, H. H., Jang, Y., Lin, T., Adamski, C. J., \u2026 Zoghbi,H. Y. (2022). Cross-species genetic screens identify transglutaminase 5 as a regulator of polyglutamine-expanded ataxin-1. Journal of Clinical Investigation, 132(9). https:\/\/doi.org\/10.1172\/JCI156616.","DOI":"10.1172\/JCI156616."},{"issue":"1","key":"1981_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103536","volume":"25","author":"U del Castillo","year":"2022","unstructured":"del Castillo U, Norkett R, Lu W, Serpinskaya A, Gelfand VI. Ataxin-2 is essential for cytoskeletal dynamics and neurodevelopment in Drosophila. iScience. 2022;25(1):103536. https:\/\/doi.org\/10.1016\/j.isci.2021.103536.","journal-title":"iScience"},{"issue":"12","key":"1981_CR102","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/hmg\/ddh139","volume":"13","author":"D Helmlinger","year":"2004","unstructured":"Helmlinger D, Hardy S, Sasorith S, Klein F, Robert F, Weber C, et al. Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum Mol Genet. 2004;13(12):1257\u201365. https:\/\/doi.org\/10.1093\/hmg\/ddh139.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"1981_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/life15111751","volume":"15","author":"L Pansera","year":"2025","unstructured":"Pansera L, Mhalhel K, Cavallaro M, Aragona M, Laur\u00e0 R, Levanti M, et al. Zebrafish as an integrative model for central nervous system research: current advances and translational perspectives. Life. 2025;15(11):1751. https:\/\/doi.org\/10.3390\/life15111751.","journal-title":"Life"},{"issue":"7446","key":"1981_CR104","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature12111","volume":"496","author":"K Howe","year":"2013","unstructured":"Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature. 2013;496(7446):498\u2013503. https:\/\/doi.org\/10.1038\/nature12111.","journal-title":"Nature"},{"key":"1981_CR105","doi-asserted-by":"publisher","unstructured":"Prabhudesai, S., Bensabeur, F. Z., Abdullah, R., Basak, I., Baez, S., Alves, G.,\u2026 M\u00f8ller, S. G. (2016). LRRK2 knockdown in zebrafish causes developmental defects,neuronal loss, and synuclein aggregation. Journal of Neuroscience Research, 94(8), 717\u2013735. https:\/\/doi.org\/10.1002\/jnr.23754.","DOI":"10.1002\/jnr.23754."},{"key":"1981_CR106","doi-asserted-by":"publisher","unstructured":"Banerjee B, Khrystoforova I, Polis B, Karasik D. (n.d.). Acute Hypoxia Elevates Arginase 2 and Induces Polyamine Stress Response in Zebrafish via Evolutionary-conserved Mechanism Adaptation to Nitrogen metabolism in air-breathing fishes View project Developing novel therapeutic agents for Alzheimer\u2019s disease View project. https:\/\/doi.org\/10.21203\/rs.3.rs-595067\/v1","DOI":"10.21203\/rs.3.rs-595067\/v1"},{"key":"1981_CR107","doi-asserted-by":"publisher","unstructured":"Zhang T, Peterson RT. (2020). Modeling Lysosomal Storage Diseases in the Zebrafish. Frontiers in Molecular Biosciences, 7. https:\/\/doi.org\/10.3389\/fmolb.2020.00082","DOI":"10.3389\/fmolb.2020.00082"},{"key":"1981_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213979","author":"TO Kolesnikova","year":"2022","unstructured":"Kolesnikova TO, Demin KA, Costa FV, Zabegalov KN, de Abreu MS, Gerasimova EV, et al. Towards Zebrafish Models of CNS Channelopathies. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232213979.","journal-title":"Int J Mol Sci"},{"key":"1981_CR109","doi-asserted-by":"publisher","unstructured":"Namikawa K, Pose-M\u00e9ndez S, K\u00f6ster RW. (2025, December 1). Genetic modeling of degenerative diseases and mechanisms of neuronal regeneration in the zebrafish cerebellum. Cellular and Molecular Life Sciences. Springer Science and Business Media Deutschland GmbH. https:\/\/doi.org\/10.1007\/s00018-024-05538-z","DOI":"10.1007\/s00018-024-05538-z"},{"key":"1981_CR110","doi-asserted-by":"publisher","unstructured":"Elsaey MA, Namikawa K, K\u00f6ster RW. Genetic modeling of the neurodegenerative disease spinocerebellar ataxia type 1 in Zebrafish. Int J Mol Sci. 2021;22(14). https:\/\/doi.org\/10.3390\/ijms22147351.","DOI":"10.3390\/ijms22147351"},{"key":"1981_CR111","doi-asserted-by":"publisher","unstructured":"Chia K, Klingseisen A, Sieger D, Priller J. (2022, October 13). Zebrafish as a model organism for neurodegenerative disease. Frontiers in Molecular Neuroscience. Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fnmol.2022.940484","DOI":"10.3389\/fnmol.2022.940484"},{"key":"1981_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00571-5","author":"TY Choi","year":"2021","unstructured":"Choi TY, Choi TI, Lee YR, Choe SK, Kim CH. Zebrafish as an animal model for biomedical research. Exp Mol Med. 2021. https:\/\/doi.org\/10.1038\/s12276-021-00571-5.","journal-title":"Exp Mol Med"},{"issue":"11","key":"1981_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050705","volume":"7","author":"C Yanicostas","year":"2012","unstructured":"Yanicostas C, Barbieri E, Hibi M, Brice A, Stevanin G, Soussi-Yanicostas N. Requirement for Zebrafish ataxin-7 in differentiation of photoreceptors and cerebellar neurons. PLoS One. 2012;7(11):e50705. https:\/\/doi.org\/10.1371\/journal.pone.0050705.","journal-title":"PLoS One"},{"key":"1981_CR114","doi-asserted-by":"publisher","unstructured":"Haas, E., Incebacak, R. D., Hentrich, T., Huridou, C., Schmidt, T., Casadei, N.,\u2026 H\u00fcbener-Schmid, J. (2022). A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes. Molecular Neurobiology, 59(1), 495\u2013522. https:\/\/doi.org\/10.1007\/s12035-021-02610-8.","DOI":"10.1007\/s12035-021-02610-8."},{"key":"1981_CR115","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.16.472987","author":"HP Handler","year":"2021","unstructured":"Handler HP, Duvick L, Mitchell J, Cvetanovic M, Reighard M, Soles A, et al. Disrupting ATXN1 nuclear localization in a knock-in SCA1 mouse model improves a spectrum of SCA1-like phenotypes and their brain region associated transcriptomic profiles. bioRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.12.16.472987.","journal-title":"bioRxiv"},{"issue":"6","key":"1981_CR116","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.neuron.2016.02.011","volume":"89","author":"M Ingram","year":"2016","unstructured":"Ingram M, Wozniak EAL, Duvick L, Yang R, Bergmann P, Carson R, et al. Cerebellar transcriptome profiles of ATXN1 transgenic mice reveal SCA1 disease progression and protection pathways. Neuron. 2016;89(6):1194\u2013207. https:\/\/doi.org\/10.1016\/j.neuron.2016.02.011.","journal-title":"Neuron"},{"key":"1981_CR117","doi-asserted-by":"publisher","unstructured":"White, J. J., Bosman, L. W. J., Blot, F. G. C., Os\u00f3rio, C., Kuppens, B. W., Krijnen,W. H. J. J., \u2026 Schonewille, M. (2021). Region-specific preservation of Purkinje cell morphology and motor behavior in the ATXN1[82Q] mouse model of spinocerebellar ataxia 1. Brain Pathology, 31(5). https:\/\/doi.org\/10.1111\/bpa.12946.","DOI":"10.1111\/bpa.12946."},{"key":"1981_CR118","doi-asserted-by":"publisher","unstructured":"Tichanek, F., Salomova, M., Jedlicka, J., Kuncova, J., Pitule, P., Macanova, T.,\u2026 Cendelin, J. (2020). Hippocampal mitochondrial dysfunction and psychiatric-relevant behavioral deficits in spinocerebellar ataxia 1 mouse model. Scientific Reports, 10(1). https:\/\/doi.org\/10.1038\/s41598-020-62308-0.","DOI":"10.1038\/s41598-020-62308-0."},{"issue":"7","key":"1981_CR119","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1093\/brain\/awr146","volume":"134","author":"S Huang","year":"2011","unstructured":"Huang S, Ling JJ, Yang S, Li X-J, Li S. Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor. Brain. 2011;134(7):1943\u201358. https:\/\/doi.org\/10.1093\/brain\/awr146.","journal-title":"Brain"},{"key":"1981_CR120","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.nbd.2014.09.020","volume":"73","author":"PM Switonski","year":"2015","unstructured":"Switonski PM, Szlachcic WJ, Krzyzosiak WJ, Figiel M. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3\/MJD. Neurobiol Dis. 2015;73:174\u201388. https:\/\/doi.org\/10.1016\/j.nbd.2014.09.020.","journal-title":"Neurobiol Dis"},{"issue":"43","key":"1981_CR121","doi-asserted-by":"publisher","first-page":"17693","DOI":"10.1073\/pnas.1212786109","volume":"109","author":"T Unno","year":"2012","unstructured":"Unno T, Wakamori M, Koike M, Uchiyama Y, Ishikawa K, Kubota H, et al. Development of Purkinje cell degeneration in a knockin mouse model reveals lysosomal involvement in the pathogenesis of SCA6. Proc Natl Acad Sci U S A. 2012;109(43):17693\u20138. https:\/\/doi.org\/10.1073\/pnas.1212786109.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1981_CR122","doi-asserted-by":"publisher","unstructured":"Duvick, L., Southern, W. M., Benzow, K., Burch, Z. N., Handler, H. P., Mitchell,J. S., \u2026 Orr, H. T. (2023). Delineating regional vulnerability in the neurodegenerative disease SCA1 using a conditional mutant ATXN1 mouse. bioRxiv: the preprint server for biology. https:\/\/doi.org\/10.1101\/2023.02.08.527710.","DOI":"10.1101\/2023.02.08.527710."},{"key":"1981_CR123","doi-asserted-by":"publisher","unstructured":"Duvick, L., Southern, W. M., Benzow, K. A., Burch, Z. N., Handler, H. P., Mitchell,J. S., \u2026 Orr, H. T. (2024). Mapping SCA1 regional vulnerabilities reveals neural and skeletal muscle contributions to disease. JCI Insight, 9(9). https:\/\/doi.org\/10.1172\/jci.insight.176057.","DOI":"10.1172\/jci.insight.176057."},{"key":"1981_CR124","doi-asserted-by":"crossref","unstructured":"Huynh DP, Figueroa K, Hoang N, Pulst S-M. (2000). Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human (Vol. 26). Retrieved from http:\/\/genetics.nature.com","DOI":"10.1038\/79162"},{"issue":"3","key":"1981_CR125","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.neulet.2005.09.020","volume":"392","author":"J Aguiar","year":"2006","unstructured":"Aguiar J, Fern\u00e1ndez J, Aguilar A, Mendoza Y, V\u00e1zquez M, Su\u00e1rez J, et al. Ubiquitous expression of human SCA2 gene under the regulation of the SCA2 self promoter cause specific Purkinje cell degeneration in transgenic mice. Neurosci Lett. 2006;392(3):202\u20136. https:\/\/doi.org\/10.1016\/j.neulet.2005.09.020.","journal-title":"Neurosci Lett"},{"issue":"9","key":"1981_CR126","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ame2.70047","volume":"8","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Li Y, Zhang L, Li Z, Lin K, Huang K, et al. Establishment of a humanized SCA2 mouse model carrying a CAA disruption preventing CAG repeat expansion in pathogenic genes. Anim Models Exp Med. 2025;8(9):1677\u201387. https:\/\/doi.org\/10.1002\/ame2.70047.","journal-title":"Anim Models Exp Med"},{"key":"1981_CR127","doi-asserted-by":"publisher","unstructured":"Cemal, C. K., Carroll, C. J., Lawrence, L., Lowrie, M. B., Ruddle, P., Al-Mahdawi,S., \u2026 Chamberlain, S. (2002). YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Human molecular genetics, 11(9), 1075\u201394. https:\/\/doi.org\/10.1093\/hmg\/11.9.1075.","DOI":"10.1093\/hmg\/11.9.1075."},{"issue":"36","key":"1981_CR128","doi-asserted-by":"publisher","first-page":"13002","DOI":"10.1523\/JNEUROSCI.2789-11.2011","volume":"31","author":"VG Shakkottai","year":"2011","unstructured":"Shakkottai VG, Costa MdoC, Dell\u2019Orco JM, Sankaranarayanan A, Wulff H, Paulson HL. Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci. 2011;31(36):13002\u201314. https:\/\/doi.org\/10.1523\/JNEUROSCI.2789-11.2011.","journal-title":"J Neurosci"},{"key":"1981_CR129","doi-asserted-by":"publisher","unstructured":"Toonen, L. J. A., Overzier, M., Evers, M. M., Leon, L. G., Van Der Zeeuw, S. A. J.,Mei, H., \u2026 Van Roon-Mom, W. M. C. (2018). Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model. Molecular Neurodegeneration, 13(1). https:\/\/doi.org\/10.1186\/s13024-018-0261-9.","DOI":"10.1186\/s13024-018-0261-9."},{"key":"1981_CR130","doi-asserted-by":"publisher","unstructured":"Konno, A., Shuvaev, A. N., Miyake, N., Miyake, K., Iizuka, A., Matsuura, S., \u2026 Hirai,H. (2014). Mutant Ataxin-3 with an Abnormally Expanded Polyglutamine Chain Disrupts Dendritic Development and Metabotropic Glutamate Receptor Signaling in Mouse Cerebellar Purkinje Cells. The Cerebellum, 13(1), 29\u201341. https:\/\/doi.org\/10.1007\/s12311-013-0516-5.","DOI":"10.1007\/s12311-013-0516-5."},{"key":"1981_CR131","doi-asserted-by":"crossref","unstructured":"Watase, K., Barrett, C. F., Miyazaki, T., Ishiguro, T., Ishikawa, K., Hu, Y., \u2026 Zoghbi,H. Y. (2008). Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant Ca V 2.1 channels. Retrieved from www.pnas.org\/cgi\/content\/full\/.","DOI":"10.1073\/pnas.0804350105"},{"key":"1981_CR132","doi-asserted-by":"publisher","unstructured":"Chang HHV, Cook AA, Watt AJ, Cullen KE. Loss of Flocculus Purkinje Cell Firing Precision Leads to Impaired Gaze Stabilization in a Mouse Model of Spinocerebellar Ataxia Type 6 (SCA6). Cells. 2022;11(17). https:\/\/doi.org\/10.3390\/cells11172739.","DOI":"10.3390\/cells11172739"},{"key":"1981_CR133","doi-asserted-by":"publisher","unstructured":"Huang, H., Charron, T. L., Fu, M., Dunn, M., Jones, D. M., Kumar, P., \u2026 Shakkottai,V. G. (2025). Resilience to Endoplasmic Reticulum Stress Mitigates Membrane Hyperexcitability Underlying Late Disease Onset in a Murine Model of SCA6. Annals of Neurology. https:\/\/doi.org\/10.1002\/ana.78042.","DOI":"10.1002\/ana.78042."},{"issue":"2","key":"1981_CR134","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12311-008-0027-y","volume":"7","author":"G Garden","year":"2008","unstructured":"Garden G, La Spada AR. Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration. Cerebellum. 2008;7(2):138\u201349. https:\/\/doi.org\/10.1007\/s12311-008-0027-y.","journal-title":"Cerebellum"},{"key":"1981_CR135","doi-asserted-by":"publisher","unstructured":"Niewiadomska-Cimicka, A., Doussau, F., Perot, J. B., Roux, M. J., Keime, C., Hache,A., \u2026 Trottier, Y. (2021). SCA7 mouse cerebellar pathology reveals preferential downregulation of key Purkinje cell-identity genes and shared disease signature with SCA1 and SCA2.Journal of Neuroscience, 41(22), 4910\u20134936. https:\/\/doi.org\/10.1523\/JNEUROSCI.1882-20.2021.","DOI":"10.1523\/JNEUROSCI.1882-20.2021."},{"issue":"13","key":"1981_CR136","doi-asserted-by":"publisher","first-page":"8283","DOI":"10.1074\/jbc.M709674200","volume":"283","author":"MJ Friedman","year":"2008","unstructured":"Friedman MJ, Wang C-E, Li X-J, Li S. Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity. J Biol Chem. 2008;283(13):8283\u201390. https:\/\/doi.org\/10.1074\/jbc.M709674200.","journal-title":"J Biol Chem"},{"key":"1981_CR137","doi-asserted-by":"publisher","unstructured":"Liu, Q., Huang, S., Yin, P., Yang, S., Zhang, J., Jing, L., \u2026 Li, S. (2020). Cerebellum-enriched protein INPP5A contributes to selective neuropathology in mouse model of spinocerebellar ataxias type 17. Nature Communications, 11(1). https:\/\/doi.org\/10.1038\/s41467-020-14931-8.","DOI":"10.1038\/s41467-020-14931-8."},{"issue":"1","key":"1981_CR138","doi-asserted-by":"publisher","DOI":"10.1080\/21675511.2016.1223580","volume":"4","author":"S Yang","year":"2016","unstructured":"Yang S, Li X-J, Li S. Molecular mechanisms underlying Spinocerebellar Ataxia 17 (SCA17) pathogenesis. Rare Dis. 2016;4(1):e1223580. https:\/\/doi.org\/10.1080\/21675511.2016.1223580.","journal-title":"Rare Dis"},{"key":"1981_CR139","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejphar.2015.03.046","volume":"759","author":"TF Vandamme","year":"2015","unstructured":"Vandamme TF. Rodent models for human diseases. Eur J Pharmacol. 2015;759:84\u20139. https:\/\/doi.org\/10.1016\/j.ejphar.2015.03.046.","journal-title":"Eur J Pharmacol"},{"key":"1981_CR140","doi-asserted-by":"publisher","unstructured":"Verdier J-M, Acquatella I, Lautier C, Devau G, Trouche S, Lasbleiz C, Mestre-Franc\u00e9s N. (2015). Lessons from the analysis of nonhuman primates for understanding human aging and neurodegenerative diseases. Frontiers in Neuroscience, 9. https:\/\/doi.org\/10.3389\/fnins.2015.00064","DOI":"10.3389\/fnins.2015.00064"},{"issue":"6","key":"1981_CR141","doi-asserted-by":"publisher","first-page":"248","DOI":"10.5607\/en25031","volume":"34","author":"K Kim","year":"2025","unstructured":"Kim K, Kim A, Won J, Park J, Lim KS, Jeon C-Y, et al. Ataxin-3 overexpression via adeno-associated viral vector injection in the primate cerebellum: a novel model of spinocerebellar ataxia type 3. Exp Neurobiol. 2025;34(6):248\u201362. https:\/\/doi.org\/10.5607\/en25031.","journal-title":"Exp Neurobiol"},{"issue":"1","key":"1981_CR142","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00018-025-05668-y","volume":"82","author":"R Mishra","year":"2025","unstructured":"Mishra R, Upadhyay A. An update on mammalian and non-mammalian animal models for biomarker development in neurodegenerative disorders. Cell Mol Life Sci. 2025;82(1):147. https:\/\/doi.org\/10.1007\/s00018-025-05668-y.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"1981_CR143","doi-asserted-by":"publisher","first-page":"263","DOI":"10.24272\/j.issn.2095-8137.2023.197","volume":"45","author":"M-T Pan","year":"2024","unstructured":"Pan M-T, Zhang H, Li X-J, Guo X-Y. Genetically modified non-human primate models for research on neurodegenerative diseases. Zool Res. 2024;45(2):263\u201374. https:\/\/doi.org\/10.24272\/j.issn.2095-8137.2023.197.","journal-title":"Zool Res"},{"key":"1981_CR144","doi-asserted-by":"publisher","unstructured":"Tomioka, I., Ishibashi, H., Minakawa, E. N., Motohashi, H. H., Takayama, O., Saito,Y., \u2026 Seki, K. (2017). Transgenic Monkey Model of the Polyglutamine Diseases Recapitulating Progressive Neurological Symptoms. eneuro, 4(2), ENEURO.0250-16.2017. https:\/\/doi.org\/10.1523\/ENEURO.0250-16.2017.","DOI":"10.1523\/ENEURO.0250-16.2017."},{"issue":"5","key":"1981_CR145","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/biolre\/iox129","volume":"97","author":"I Tomioka","year":"2017","unstructured":"Tomioka I, Nogami N, Nakatani T, Owari K, Fujita N, Motohashi H, et al. Generation of transgenic marmosets using a tetracyclin-inducible transgene expression system as a neurodegenerative disease model\u2020. Biol Reprod. 2017;97(5):772\u201380. https:\/\/doi.org\/10.1093\/biolre\/iox129.","journal-title":"Biol Reprod"},{"key":"1981_CR146","doi-asserted-by":"publisher","unstructured":"Tomioka I, Nagai Y, Seki K. (2020, September 24). Generation of Common Marmoset Model Lines of Spinocerebellar Ataxia Type 3. Frontiers in Neuroscience. Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fnins.2020.548002","DOI":"10.3389\/fnins.2020.548002"},{"issue":"2","key":"1981_CR147","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ncl.2020.01.008","volume":"38","author":"KT Kwei","year":"2020","unstructured":"Kwei KT, Kuo S-H. An Overview of the Current State and the Future of Ataxia Treatments. Neurol Clin. 2020;38(2):449\u201367. https:\/\/doi.org\/10.1016\/j.ncl.2020.01.008.","journal-title":"Neurol Clin"},{"key":"1981_CR148","doi-asserted-by":"publisher","unstructured":"Miyai, I., Ito, M., Hattori, N., Mihara, M., Hatakenaka, M., Yagura, H., \u2026 Nishizawa,M. (2012). Cerebellar Ataxia Rehabilitation Trial in Degenerative Cerebellar Diseases.Neurorehabilitation and Neural Repair, 26(5), 515\u2013522. https:\/\/doi.org\/10.1177\/1545968311425918.","DOI":"10.1177\/1545968311425918."},{"issue":"3","key":"1981_CR149","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12311-019-1006-1","volume":"18","author":"K Tercero-P\u00e9rez","year":"2019","unstructured":"Tercero-P\u00e9rez K, Cort\u00e9s H, Torres-Ramos Y, Rodr\u00edguez-Labrada R, Cerecedo-Zapata CM, Hern\u00e1ndez-Hern\u00e1ndez O, et al. Effects of physical rehabilitation in patients with spinocerebellar ataxia type 7. Cerebellum. 2019;18(3):397\u2013405. https:\/\/doi.org\/10.1007\/s12311-019-1006-1.","journal-title":"Cerebellum"},{"issue":"4","key":"1981_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102317","volume":"35","author":"KJ Fagan","year":"2024","unstructured":"Fagan KJ, Chillon G, Carrell EM, Waxman EA, Davidson BL. Cas9 editing of ATXN1 in a spinocerebellar ataxia type 1 mice and human iPSC-derived neurons. Mol Ther Nucleic Acids. 2024;35(4):102317. https:\/\/doi.org\/10.1016\/j.omtn.2024.102317.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"1981_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24299-y","volume":"12","author":"M Pappad\u00e0","year":"2022","unstructured":"Pappad\u00e0 M, Bonuccelli O, Buratto M, Fontana R, Sicurella M, Caproni A, et al. Suppressing gain-of-function proteins via CRISPR\/Cas9 system in SCA1 cells. Sci Rep. 2022;12(1):20285. https:\/\/doi.org\/10.1038\/s41598-022-24299-y.","journal-title":"Sci Rep"},{"key":"1981_CR152","doi-asserted-by":"publisher","unstructured":"Scoles, D. R., Dansithong, W., Pflieger, L. T., Paul, S., Gandelman, M., Figueroa,K. P., \u2026 Pulst, S. M. (2020). ALS-associated genes in SCA2 mouse spinal cord transcriptomes.Human Molecular Genetics, 29(10), 1658\u20131672. https:\/\/doi.org\/10.1093\/hmg\/ddaa072.","DOI":"10.1093\/hmg\/ddaa072."},{"key":"1981_CR153","doi-asserted-by":"publisher","unstructured":"Bushart, D. D., Zalon, A. J., Zhang, H., Morrison, L. M., Guan, Y., Paulson, H. L.,\u2026 McLoughlin, H. S. (2021). Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channel\u2013Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3. The Cerebellum, 20(1), 41\u201353. https:\/\/doi.org\/10.1007\/s12311-020-01179-7.","DOI":"10.1007\/s12311-020-01179-7."},{"key":"1981_CR154","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.nbd.2013.04.019","volume":"58","author":"MM Evers","year":"2013","unstructured":"Evers MM, Tran HD, Zalachoras I, Pepers BA, Meijer OC, den Dunnen JT, et al. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Neurobiol Dis. 2013;58:49\u201356. https:\/\/doi.org\/10.1016\/j.nbd.2013.04.019.","journal-title":"Neurobiol Dis"},{"key":"1981_CR155","doi-asserted-by":"publisher","unstructured":"Hu, J., Gagnon, K. T., Liu, J., Watts, J. K., Syeda-Nawaz, J., Bennett, C. F., \u2026Corey, D. R. (2011). Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. Biological Chemistry, 392(4). https:\/\/doi.org\/10.1515\/bc.2011.045.","DOI":"10.1515\/bc.2011.045."},{"issue":"1","key":"1981_CR156","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/ana.25264","volume":"84","author":"HS McLoughlin","year":"2018","unstructured":"McLoughlin HS, Moore LR, Chopra R, Komlo R, McKenzie M, Blumenstein KG, et al. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. Ann Neurol. 2018;84(1):64\u201377. https:\/\/doi.org\/10.1002\/ana.25264.","journal-title":"Ann Neurol"},{"key":"1981_CR157","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.omtn.2017.04.005","volume":"7","author":"LR Moore","year":"2017","unstructured":"Moore LR, Rajpal G, Dillingham IT, Qutob M, Blumenstein KG, Gattis D, et al. Evaluation of antisense oligonucleotides targeting ATXN3 in SCA3 mouse models. Mol Ther Nucleic Acids. 2017;7:200\u201310. https:\/\/doi.org\/10.1016\/j.omtn.2017.04.005.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1981_CR158","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.omtn.2017.06.019","volume":"8","author":"LJA Toonen","year":"2017","unstructured":"Toonen LJA, Rigo F, van Attikum H, van Roon-Mom WMC. Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice. Mol Ther Nucleic Acids. 2017;8:232\u201342. https:\/\/doi.org\/10.1016\/j.omtn.2017.06.019.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1981_CR159","doi-asserted-by":"publisher","unstructured":"Schuster, K. H., DiFranco, D. M., Putka, A. F., Mato, J. P., Jarrah, S. I., Stec,N. R., \u2026 McLoughlin, H. S. (2023). Disease-associated oligodendrocyte signatures are spatiotemporally dysregulated in spinocerebellar ataxia type 3. Frontiers in Neuroscience, 17. https:\/\/doi.org\/10.3389\/fnins.2023.1118429.","DOI":"10.3389\/fnins.2023.1118429."},{"key":"1981_CR160","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.omtn.2021.11.015","volume":"27","author":"S Hauser","year":"2022","unstructured":"Hauser S, Helm J, Kraft M, Korneck M, H\u00fcbener-Schmid J, Sch\u00f6ls L. Allele-specific targeting of mutant ataxin-3 by antisense oligonucleotides in SCA3-iPSC-derived neurons. Mol Ther Nucleic Acids. 2022;27:99\u2013108. https:\/\/doi.org\/10.1016\/j.omtn.2021.11.015.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1981_CR161","doi-asserted-by":"publisher","unstructured":"Nobre, R. J., Lobo, D. D., Henriques, C., Duarte, S. P., Lopes, S. M., Silva, A.C., \u2026 Toonen, L. J. A. (2022). MiRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3. Nucleic Acid Therapeutics, 32(3), 194\u2013205. https:\/\/doi.org\/10.1089\/nat.2021.0020.","DOI":"10.1089\/nat.2021.0020."},{"key":"1981_CR162","doi-asserted-by":"publisher","unstructured":"Alves, S., Nascimento-Ferreira, I., Auregan, G., Hassig, R., Dufour, N., Brouillet,E., \u2026 D\u00e9glon, N. (2008). Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS ONE, 3(10). https:\/\/doi.org\/10.1371\/journal.pone.0003341.","DOI":"10.1371\/journal.pone.0003341."},{"key":"1981_CR163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100086","author":"C N\u00f3brega","year":"2014","unstructured":"N\u00f3brega C, Nascimento-Ferreira I, Onofre I, Albuquerque D, D\u00e9glon N, De Almeida LP. RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of Machado-Joseph disease. PLoS One. 2014. https:\/\/doi.org\/10.1371\/journal.pone.0100086.","journal-title":"PLoS One"},{"key":"1981_CR164","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.biomaterials.2015.12.021","volume":"82","author":"M Concei\u00e7\u00e3o","year":"2016","unstructured":"Concei\u00e7\u00e3o M, Mendon\u00e7a L, N\u00f3brega C, Gomes C, Costa P, Hirai H, et al. Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype. Biomaterials. 2016;82:124\u201337. https:\/\/doi.org\/10.1016\/j.biomaterials.2015.12.021.","journal-title":"Biomaterials"},{"issue":"1","key":"1981_CR165","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/lifemedi\/lnac020","volume":"1","author":"G Song","year":"2022","unstructured":"Song G, Ma Y, Gao X, Zhang X, Zhang F, Tian C, et al. CRISPR\/Cas9-mediated genetic correction reverses spinocerebellar ataxia 3 disease-associated phenotypes in differentiated cerebellar neurons. Life Med. 2022;1(1):27\u201344. https:\/\/doi.org\/10.1093\/lifemedi\/lnac020.","journal-title":"Life Med"},{"issue":"4","key":"1981_CR166","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1089\/oli.2005.15.298","volume":"15","author":"T Kubodera","year":"2005","unstructured":"Kubodera T, Yokota T, Ishikawa K, Mizusawa H. New RNAi strategy for selective suppression of a mutant allele in polyglutamine disease. Oligonucleotides. 2005;15(4):298\u2013302. https:\/\/doi.org\/10.1089\/oli.2005.15.298.","journal-title":"Oligonucleotides"},{"issue":"347","key":"1981_CR167","doi-asserted-by":"publisher","first-page":"347ra94","DOI":"10.1126\/scitranslmed.aaf5660","volume":"8","author":"Y Miyazaki","year":"2016","unstructured":"Miyazaki Y, Du X, Muramatsu S. An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron. Sci Transl Med. 2016;8(347):347ra94-347ra94. https:\/\/doi.org\/10.1126\/scitranslmed.aaf5660.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1981_CR168","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12311-018-0917-6","volume":"17","author":"PDH Pastor","year":"2018","unstructured":"Pastor PDH, Du X, Fazal S, Davies AN, Gomez CM. Targeting the CACNA1A IRES as a treatment for spinocerebellar ataxia type 6. Cerebellum. 2018;17(1):72\u20137. https:\/\/doi.org\/10.1007\/s12311-018-0917-6.","journal-title":"Cerebellum"},{"key":"1981_CR169","doi-asserted-by":"crossref","unstructured":"Niu, C., Prakash, T. P., Kim, A., Quach, J. L., Huryn, L. A., Yang, Y., \u2026 La Spada,A. R. (2018). Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7. Sci. Transl. Med (Vol. 10). Retrieved from http:\/\/stm.sciencemag.org\/.","DOI":"10.1126\/scitranslmed.aap8677"},{"issue":"9","key":"1981_CR170","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/mt.2014.108","volume":"22","author":"PS Ramachandran","year":"2014","unstructured":"Ramachandran PS, Boudreau RL, Schaefer KA, La Spada AR, Davidson BL. Nonallele specific silencing of Ataxin-7 improves disease phenotypes in a mouse model of SCA7. Mol Ther. 2014;22(9):1635\u201342. https:\/\/doi.org\/10.1038\/mt.2014.108.","journal-title":"Mol Ther"},{"issue":"10","key":"1981_CR171","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/ejhg.2014.39","volume":"22","author":"J Scholefield","year":"2014","unstructured":"Scholefield J, Watson L, Smith D, Greenberg J, Wood MJ. Allele-specific silencing of mutant Ataxin-7 in SCA7 patient-derived fibroblasts. Eur J Hum Genet. 2014;22(10):1369\u201375. https:\/\/doi.org\/10.1038\/ejhg.2014.39.","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"1981_CR172","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007232","volume":"4","author":"J Scholefield","year":"2009","unstructured":"Scholefield J, Greenberg LJ, Weinberg MS, Arbuthnot PB, Abdelgany A, Wood MJA. Design of RNAi hairpins for mutation-specific silencing of Ataxin-7 and correction of a SCA7 phenotype. PLoS One. 2009;4(9):e7232. https:\/\/doi.org\/10.1371\/journal.pone.0007232.","journal-title":"PLoS One"},{"issue":"13","key":"1981_CR173","doi-asserted-by":"publisher","first-page":"7870","DOI":"10.1093\/nar\/gkx483","volume":"45","author":"HJ Curtis","year":"2018","unstructured":"Curtis HJ, Seow Y, Wood MJA, Varela MA. Knockdown and replacement therapy mediated by artificial mirtrons in spinocerebellar ataxia 7. Nucleic Acids Res. 2018;45(13):7870\u201385. https:\/\/doi.org\/10.1093\/nar\/gkx483.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"1981_CR174","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084354","volume":"25","author":"A Niewiadomska-Cimicka","year":"2024","unstructured":"Niewiadomska-Cimicka A, Fievet L, Surdyka M, Jesion E, Keime C, Singer E, et al. AAV-mediated CAG-targeting selectively reduces polyglutamine-expanded protein and attenuates disease phenotypes in a spinocerebellar ataxia mouse model. Int J Mol Sci. 2024;25(8):4354. https:\/\/doi.org\/10.3390\/ijms25084354.","journal-title":"Int J Mol Sci"},{"key":"1981_CR175","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084249","author":"R Afonso-Reis","year":"2021","unstructured":"Afonso-Reis R, Afonso IT, N\u00f3brega C, MDPI. Current status of gene therapy research in polyglutamine spinocerebellar ataxias. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22084249.","journal-title":"Int J Mol Sci"},{"key":"1981_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111499","author":"CS McIntosh","year":"2021","unstructured":"McIntosh CS, Li D, Wilton SD, Aung-Htut MT. Polyglutamine ataxias: our current molecular understanding and what the future holds for antisense therapies. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/biomedicines9111499.","journal-title":"Biomedicines"},{"key":"1981_CR177","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28819","author":"Y V\u00e1zquez-Mojena","year":"2021","unstructured":"V\u00e1zquez-Mojena Y, Le\u00f3n-Arcia K, Gonz\u00e1lez-Zaldivar Y, Rodr\u00edguez-Labrada R, Vel\u00e1zquez-P\u00e9rez L. Gene therapy for polyglutamine spinocerebellar ataxias: advances, challenges, and perspectives. Mov Disord. 2021. https:\/\/doi.org\/10.1002\/mds.28819.","journal-title":"Mov Disord"},{"issue":"8","key":"1981_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102228","volume":"298","author":"DR Scoles","year":"2022","unstructured":"Scoles DR, Gandelman M, Paul S, Dexheimer T, Dansithong W, Figueroa KP, et al. A quantitative high-throughput screen identifies compounds that lower expression of the SCA2-and ALS-associated gene ATXN2. J Biol Chem. 2022;298(8):102228. https:\/\/doi.org\/10.1016\/j.jbc.2022.102228.","journal-title":"J Biol Chem"},{"issue":"23","key":"1981_CR179","doi-asserted-by":"publisher","DOI":"10.3390\/cells12232735","volume":"12","author":"FV Borbolla-Jim\u00e9nez","year":"2023","unstructured":"Borbolla-Jim\u00e9nez FV, Garc\u00eda-Aguirre IA, Del Prado-Audelo ML, Hern\u00e1ndez-Hern\u00e1ndez O, Cisneros B, Leyva-G\u00f3mez G, et al. Development of a polymeric pharmacological nanocarrier system as a potential therapy for spinocerebellar ataxia type 7. Cells. 2023;12(23):2735. https:\/\/doi.org\/10.3390\/cells12232735.","journal-title":"Cells"},{"issue":"5","key":"1981_CR180","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.ymthe.2024.02.033","volume":"32","author":"KH Schuster","year":"2024","unstructured":"Schuster KH, Zalon AJ, DiFranco DM, Putka AF, Stec NR, Jarrah SI, et al. ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice. Molecular therapy\u202f: the journal of the American Society of Gene Therapy. 2024;32(5):1359\u201372. https:\/\/doi.org\/10.1016\/j.ymthe.2024.02.033.","journal-title":"Molecular therapy : the journal of the American Society of Gene Therapy"},{"key":"1981_CR181","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-023-01520-w","author":"KS Marinina","year":"2023","unstructured":"Marinina KS, Bezprozvanny IB, Egorova PA. Cognitive decline and mood alterations in the mouse model of spinocerebellar ataxia type 2. Cerebellum. 2023. https:\/\/doi.org\/10.1007\/s12311-023-01520-w.","journal-title":"Cerebellum"},{"key":"1981_CR182","doi-asserted-by":"publisher","unstructured":"Cook, A. A., Jayabal, S., Sheng, J., Fields, E., Leung, T. C. S., Quilez, S., \u2026 Watt,A. J. (2021, February 22). Restoration of BDNF-TrkB signaling rescues deficits in a mouse model of SCA6. https:\/\/doi.org\/10.1101\/2021.02.21.432180.","DOI":"10.1101\/2021.02.21.432180."},{"key":"1981_CR183","doi-asserted-by":"publisher","unstructured":"Gr\u00f6mmke, M., Schulte, H., Theis, C. D. C., Nonnweiler, L., & Mark, M. D. (2023, September 13). Reduced cerebellar Gq-protein signaling elicits early onset spatial navigation deficits in a SCA6 mouse model. https:\/\/doi.org\/10.1101\/2023.09.12.557443.","DOI":"10.1101\/2023.09.12.557443."},{"issue":"1","key":"1981_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14931-8","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu Q, Huang S, Yin P, Yang S, Zhang J, Jing L, et al. Cerebellum-enriched protein INPP5A contributes to selective neuropathology in mouse model of spinocerebellar ataxias type 17. Nat Commun. 2020;11(1):1101. https:\/\/doi.org\/10.1038\/s41467-020-14931-8.","journal-title":"Nat Commun"},{"issue":"6","key":"1981_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102162","volume":"6","author":"X Chen","year":"2025","unstructured":"Chen X, Liu X, Lin W, Zhang L, Cheng X, Huang Z, et al. Transcranial alternating current stimulation for treating spinocerebellar ataxia type 3: a randomized controlled trial. Cell Rep Med. 2025;6(6):102162. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102162.","journal-title":"Cell Rep Med"},{"key":"1981_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102952","author":"T Ishihara","year":"2024","unstructured":"Ishihara T, Tada M, Kanemitsu Y, Takahashi Y, Ishikawa K, Ikenaka K, et al. L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. E Clin Med. 2024. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102952.","journal-title":"E Clin Med"},{"issue":"6","key":"1981_CR187","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1007\/s12311-024-01714-w","volume":"23","author":"A Suppiej","year":"2024","unstructured":"Suppiej A, Ceccato C, Tzekov R, Cermakova I, Parmeggiani F, Bellucci G, et al. Long-term follow-up before and during Riluzole treatment in six patients from two families with spinocerebellar ataxia type 7. Cerebellum. 2024;23(6):2226\u201335. https:\/\/doi.org\/10.1007\/s12311-024-01714-w.","journal-title":"Cerebellum"},{"issue":"2","key":"1981_CR188","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12311-023-01548-y","volume":"23","author":"M-K Chiang","year":"2023","unstructured":"Chiang M-K, Lin T-C, Lin K-H, Chang Y-C, Hsieh-Li HM, Lai D-M. Hyperbaric oxygen therapy attenuated the motor coordination and cognitive impairment of polyglutamine spinocerebellar ataxia SCA17 mice. Cerebellum. 2023;23(2):401\u201317. https:\/\/doi.org\/10.1007\/s12311-023-01548-y.","journal-title":"Cerebellum"},{"key":"1981_CR189","doi-asserted-by":"publisher","unstructured":"Aronson JK, Ferner RE. Biomarkers\u2014A General Review. Curr Protocols Pharmacol. 2017;76(1). https:\/\/doi.org\/10.1002\/cpph.19.","DOI":"10.1002\/cpph.19"},{"key":"1981_CR190","doi-asserted-by":"publisher","unstructured":"Klockgether T, Grobe-Einsler M, Faber J. (2025, August 1). Biomarkers in Spinocerebellar Ataxias. Cerebellum. Springer. https:\/\/doi.org\/10.1007\/s12311-025-01856-5","DOI":"10.1007\/s12311-025-01856-5"},{"key":"1981_CR191","doi-asserted-by":"publisher","unstructured":"Prudencio, M., Garcia-Moreno, H., Jansen-West, K. R., AL-Shaikh, R. H., Gendron,T. F., Heckman, M. G., \u2026 Petrucelli, L. (2020). Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. Science Translational Medicine, 12(566). https:\/\/doi.org\/10.1126\/scitranslmed.abb7086.","DOI":"10.1126\/scitranslmed.abb7086."},{"issue":"11","key":"1981_CR192","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/mds.28749","volume":"36","author":"J H\u00fcbener-Schmid","year":"2021","unstructured":"H\u00fcbener-Schmid J, Kuhlbrodt K, Peladan J, Faber J, Santana MM, Hengel H, et al. Polyglutamine\u2010expanded Ataxin\u20103: a target engagement marker for spinocerebellar ataxia type 3 in peripheral blood. Mov Disord. 2021;36(11):2675\u201381. https:\/\/doi.org\/10.1002\/mds.28749.","journal-title":"Mov Disord"},{"key":"1981_CR193","doi-asserted-by":"publisher","unstructured":"Berger, M., Garcia-Moreno, H., Ferreira, M., Hubener-Schmid, J., Schaprian, T., Wegner,P., \u2026 Faber, J. (2025, January 31). Progression of biological markers in spinocerebellar ataxia type 3: analysis of longitudinal data from the ESMI cohort. https:\/\/doi.org\/10.1101\/2025.01.30.25321426.","DOI":"10.1101\/2025.01.30.25321426."},{"key":"1981_CR194","doi-asserted-by":"publisher","unstructured":"Tezenas du Montcel, S., Petit, E., Olubajo, T., Faber, J., Lallemant-Dudek, P., Bushara,K., \u2026 Ashizawa, T. (2023). Baseline Clinical and Blood Biomarkers in Patients With Preataxic and Early-Stage Disease Spinocerebellar Ataxia 1 and 3. Neurology, 100(17). https:\/\/doi.org\/10.1212\/WNL.0000000000207088.","DOI":"10.1212\/WNL.0000000000207088."},{"issue":"11","key":"1981_CR195","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115070","volume":"26","author":"R Hanna Al-Shaikh","year":"2025","unstructured":"Hanna Al-Shaikh R, Jansen-West K, Strongosky A, Parrales Z, Dunmore JA, Song Y, et al. Evaluating glial fibrillary acidic protein and neurofilament light as potential biomarkers for spinocerebellar ataxia 7. Int J Mol Sci. 2025;26(11):5070. https:\/\/doi.org\/10.3390\/ijms26115070.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1981_CR196","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s12311-018-0947-0","volume":"17","author":"Y Torres-Ramos","year":"2018","unstructured":"Torres-Ramos Y, Montoya-Estrada A, Cisneros B, Tercero-P\u00e9rez K, Le\u00f3n-Reyes G, Leyva-Garc\u00eda N, et al. Oxidative stress in spinocerebellar ataxia type 7 is associated with disease severity. Cerebellum. 2018;17(5):601\u20139. https:\/\/doi.org\/10.1007\/s12311-018-0947-0.","journal-title":"Cerebellum"},{"issue":"9","key":"1981_CR197","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1007\/s12035-019-1480-y","volume":"56","author":"VM Borgonio-Cuadra","year":"2019","unstructured":"Borgonio-Cuadra VM, Valdez-vargas C, Romero-c\u00f3rdoba S, Hidalgo-miranda A, Tapia-guerrero Y, Cerecedo-zapata CM, et al. Wide profiling of circulating microRNAs in spinocerebellar ataxia type 7. Mol Neurobiol. 2019;56(9):6106\u201320.","journal-title":"Mol Neurobiol"},{"key":"1981_CR198","doi-asserted-by":"publisher","DOI":"10.3390\/biom10030390","author":"R Nambo-Venegas","year":"2020","unstructured":"Nambo-Venegas R, Valdez-Vargas C, Cisneros B, Palacios-Gonz\u00e1lez B, Vela-Amieva M, Ibarra-Gonz\u00e1lez I, et al. Altered plasma acylcarnitines and amino acids profile in spinocerebellar ataxia type 7. Biomolecules. 2020. https:\/\/doi.org\/10.3390\/biom10030390.","journal-title":"Biomolecules"},{"key":"1981_CR199","doi-asserted-by":"publisher","unstructured":"Reetz, K., Lencer, R., Hagenah, J. M., Gaser, C., Tadic, V., Walter, U., \u2026 Binkofski,F. (2010). Structural Changes Associated with Progression of Motor Deficits in Spinocerebellar Ataxia 17. The Cerebellum, 9(2), 210\u2013217. https:\/\/doi.org\/10.1007\/s12311-009-0150-4.","DOI":"10.1007\/s12311-009-0150-4."},{"key":"1981_CR200","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.nicl.2018.06.011","volume":"19","author":"IM Adanyeguh","year":"2018","unstructured":"Adanyeguh IM, Perlbarg V, Henry P-G, Rinaldi D, Petit E, Valabregue R, et al. Autosomal dominant cerebellar ataxias: imaging biomarkers with high effect sizes. NeuroImage: Clinical. 2018;19:858\u201367. https:\/\/doi.org\/10.1016\/j.nicl.2018.06.011.","journal-title":"NeuroImage: Clinical"},{"key":"1981_CR201","doi-asserted-by":"publisher","unstructured":"Nigri, A., Sarro, L., Mongelli, A., Pinardi, C., Porcu, L., Castaldo, A., \u2026 Nanetti,L. (2020). Progression of Cerebellar Atrophy in Spinocerebellar Ataxia Type 2 Gene Carriers:A Longitudinal MRI Study in Preclinical and Early Disease Stages. Frontiers in Neurology, 11. https:\/\/doi.org\/10.3389\/fneur.2020.616419.","DOI":"10.3389\/fneur.2020.616419."},{"issue":"10","key":"1981_CR202","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/mds.29934","volume":"39","author":"TJR Rezende","year":"2024","unstructured":"Rezende TJR, Petit E, Park YW, Tezenas du Montcel S, Joers JM, DuBois JM, et al. Sensitivity of advanced magnetic resonance imaging to progression over six months in early spinocerebellar ataxia. Mov Disord. 2024;39(10):1856\u201367. https:\/\/doi.org\/10.1002\/mds.29934.","journal-title":"Mov Disord"},{"key":"1981_CR203","doi-asserted-by":"publisher","unstructured":"Seemann, J., Daghsen, L., Cazier, M., Lamy, J., Welter, M., Giese, M. A., \u2026 Coarelli,G. (2024). Digital Gait Measures Capture 1-Year Progression in Early\u2010Stage Spinocerebellar Ataxia Type 2. Movement Disorders, 39(5), 788\u2013797. https:\/\/doi.org\/10.1002\/mds.29757.","DOI":"10.1002\/mds.29757."},{"issue":"3","key":"1981_CR204","first-page":"150","volume":"14","author":"R Rodr\u00edguez-Labrada","year":"2013","unstructured":"Rodr\u00edguez-Labrada R, Vel\u00e1zquez-P\u00e9rez L. Alteraciones de los movimientos oculares sac\u00e1dicos en las enfermedades poliglutam\u00ednicas. Rev Mex Neuroci. 2013;14(3):150\u20138.","journal-title":"Rev Mex Neuroci"},{"issue":"7","key":"1981_CR205","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911803","volume":"12","author":"C Wilke","year":"2020","unstructured":"Wilke C, Haas E, Reetz K, Faber J, Garcia-Moreno H, Santana MM, et al. Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Mol Med. 2020;12(7):e11803. https:\/\/doi.org\/10.15252\/emmm.201911803.","journal-title":"EMBO Mol Med"},{"key":"1981_CR206","doi-asserted-by":"publisher","unstructured":"Mengel, D., Wellik, I. G., Schuster, K. H., Jarrah, S. I., Wacker, M., Ashraf, N.S., \u2026 McLoughlin, H. S. (2023). Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3. Disease models & mechanisms, 16(9). https:\/\/doi.org\/10.1242\/dmm.050144.","DOI":"10.1242\/dmm.050144."},{"key":"1981_CR207","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062043","author":"HP Nguyen","year":"2013","unstructured":"Nguyen HP, H\u00fcbener J, Weber JJ, Grueninger S, Riess O, Weiss A. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in spinocerebellar ataxia type 3 mice. PLoS One. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0062043.","journal-title":"PLoS One"},{"key":"1981_CR208","doi-asserted-by":"publisher","unstructured":"Jansen-West, K., Todd, T. W., Daughrity, L. M., Yue, M., Tong, J., Carlomagno, Y.,\u2026 Prudencio, M. (2022). Plasma PolyQ-ATXN3 Levels Associate With Cerebellar Degeneration and Behavioral Abnormalities in a New AAV-Based SCA3 Mouse Model. Frontiers in Cell and Developmental Biology, 10. https:\/\/doi.org\/10.3389\/fcell.2022.863089.","DOI":"10.3389\/fcell.2022.863089."},{"issue":"1","key":"1981_CR209","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-29070-7","volume":"15","author":"LE Almaguer-Mederos","year":"2025","unstructured":"Almaguer-Mederos LE, Key J, Sen N-E, Canet-Pons J, D\u00f6ring C, Meierhofer D, et al. Multiomics approach identifies SERPINB1 as candidate biomarker for spinocerebellar ataxia type 2. Sci Rep. 2025;15(1):42559. https:\/\/doi.org\/10.1038\/s41598-025-29070-7.","journal-title":"Sci Rep"},{"key":"1981_CR210","doi-asserted-by":"publisher","unstructured":"Shorrock, H. K., Lennon, C. D., Aliyeva, A., Davey, E. E., DeMeo, C. C., Pritchard,C. E., \u2026 Berglund, J. A. (2024). Widespread alternative splicing dysregulation occurs presymptomatically in CAG expansion spinocerebellar ataxias. Brain: a journal of neurology, 147(2), 486\u2013504. https:\/\/doi.org\/10.1093\/brain\/awad329.","DOI":"10.1093\/brain\/awad329."},{"key":"1981_CR211","doi-asserted-by":"publisher","unstructured":"Borgonio-Cuadra, V. M., Meza-Dorantes, A., Rodr\u00edguez-P\u00e9rez, J. M., Garc\u00eda-Aguirre,I. A., Murillo-Melo, N. M., P\u00e9rez-Hern\u00e1ndez, N., \u2026 Maga\u00f1a, J. J. (2026). Integrated Plasma and Glial Cell Evidence Indicates a Functional Role for hsa-miR-342-5p in Spinocerebellar Ataxia Type 7 and Its Potential Use as a Biomarker. International journal of molecular sciences, 27(2). https:\/\/doi.org\/10.3390\/ijms27020683.","DOI":"10.3390\/ijms27020683."},{"issue":"11","key":"1981_CR212","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1002\/mds.29206","volume":"37","author":"W Ilg","year":"2022","unstructured":"Ilg W, M\u00fcller B, Faber J, van Gaalen J, Hengel H, Vogt IR, et al. Digital gait biomarkers allow to capture 1-year longitudinal change in spinocerebellar ataxia type 3. Mov Disord. 2022;37(11):2295\u2013301. https:\/\/doi.org\/10.1002\/mds.29206.","journal-title":"Mov Disord"},{"key":"1981_CR213","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2012.04.003","author":"HT Orr","year":"2012","unstructured":"Orr HT. SCA1-phosphorylation, a regulator of Ataxin-1 function and pathogenesis. Prog Neurobiol. 2012. https:\/\/doi.org\/10.1016\/j.pneurobio.2012.04.003.","journal-title":"Prog Neurobiol"},{"issue":"April","key":"1981_CR214","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12311-008-0019-y","volume":"2","author":"I Lastres-Becker","year":"2008","unstructured":"Lastres-Becker I, R\u00fcb U, Auburger G. Spinocerebellar ataxia 2 (SCA2). Cerebellum. 2008;2(April):115\u201324. https:\/\/doi.org\/10.1007\/s12311-008-0019-y .","journal-title":"Cerebellum"},{"key":"1981_CR215","doi-asserted-by":"publisher","unstructured":"Vel\u00e1zquez-P\u00e9rez LC, Rodr\u00edguez-Labrada R, Fernandez-Ruiz J. (2017). Spinocerebellar Ataxia Type 2: Clinicogenetic Aspects, Mechanistic Insights, and Management Approaches. Frontiers in Neurology, 8. https:\/\/doi.org\/10.3389\/fneur.2017.00472","DOI":"10.3389\/fneur.2017.00472"},{"key":"1981_CR216","doi-asserted-by":"crossref","unstructured":"Riess O, R\u00fcb U, Pastore A, Bauer P, Sch\u00f6ls L. (2008). SCA3: Neurological features, pathogenesis and animal models. Cerebellum, (March), 125\u201337.","DOI":"10.1007\/s12311-008-0013-4"},{"key":"1981_CR217","doi-asserted-by":"crossref","unstructured":"Du X, Gomez CM. Spinocerebellum Ataxia Type 6\u202f: Molecular Mechanisms and Calcium Channel Genetics. In: Polyglutamine Disorders. Chicago: Springer International Publishing; 2018. p. 147\u201373.","DOI":"10.1007\/978-3-319-71779-1_7"},{"key":"1981_CR218","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12311-008-0016-1","volume":"17","author":"G Stevanin","year":"2008","unstructured":"Stevanin G, Brice A, Curie M, Umr S, Fe I. Spinocerebellar ataxia 17 (SCA17) and Huntington\u2019s disease-like 4 (HDL4). Cerebellum. 2008;17:170\u20138.","journal-title":"Cerebellum"},{"key":"1981_CR219","doi-asserted-by":"publisher","unstructured":"Emamian, E. S., Kaytor, M. D., Duvick, L. A., Zu, T., Tousey, S. K., Zoghbi, H. Y.,\u2026 Orr, H. T. (2003). Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron, 38(3), 375\u201387. https:\/\/doi.org\/10.1016\/s0896-6273(03)00258-7.","DOI":"10.1016\/s0896-6273(03)00258-7."},{"key":"1981_CR220","doi-asserted-by":"publisher","unstructured":"Robinson, K. J., Tym, M. C., Hogan, A., Watchon, M., Yuan, K. C., Plenderleith, S.K., \u2026 Laird, A. S. (2021). Flow cytometry allows rapid detection of protein aggregates in cellular and zebrafish models of spinocerebellar ataxia 3. DMM Disease Models and Mechanisms, 14(10). https:\/\/doi.org\/10.1242\/dmm.049023.","DOI":"10.1242\/dmm.049023."},{"key":"1981_CR221","doi-asserted-by":"publisher","unstructured":"Wu, Y. L., Chang, J. C., Lin, W. Y., Li, C. C., Hsieh, M., Chen, H. W., \u2026 Liu, K.L. (2017). Treatment with Caffeic Acid and Resveratrol Alleviates Oxidative Stress Induced Neurotoxicity in Cell and Drosophila Models of Spinocerebellar Ataxia Type3.Scientific Reports, 7(1). https:\/\/doi.org\/10.1038\/s41598-017-11839-0.","DOI":"10.1038\/s41598-017-11839-0."},{"key":"1981_CR222","doi-asserted-by":"publisher","unstructured":"Ishiguro, T., Ishikawa, K., Takahashi, M., Obayashi, M., Amino, T., Sato, N., \u2026 Mizusawa,H. (2010). The carboxy-terminal fragment of \u03b11A calcium channel preferentially aggregates in the cytoplasm of human spinocerebellar ataxia type 6 Purkinje cells. Acta Neuropathologica, 119(4), 447\u2013464. https:\/\/doi.org\/10.1007\/s00401-009-0630-0.","DOI":"10.1007\/s00401-009-0630-0."},{"issue":"2","key":"1981_CR223","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12031-012-9722-8","volume":"47","author":"X Yu","year":"2012","unstructured":"Yu X, Ajayi A, Boga NR, Str\u00f6m AL. Differential degradation of full-length and cleaved ataxin-7 fragments in a novel stable inducible SCA7 model. J Mol Neurosci. 2012;47(2):219\u201333. https:\/\/doi.org\/10.1007\/s12031-012-9722-8.","journal-title":"J Mol Neurosci"},{"key":"1981_CR224","doi-asserted-by":"crossref","unstructured":"Ajayi, A., Yu, X., Lindberg, S., Langel, \u00dc., & Str\u00f6m, A.-L. (2012). Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCA7) model. Retrieved from http:\/\/www.biomedcentral.com\/1471-2202\/13\/86.","DOI":"10.1186\/1471-2202-13-86"},{"key":"1981_CR225","doi-asserted-by":"publisher","unstructured":"Kung, P. J., Tao, Y. C., Hsu, H. C., Chen, W. L., Lin, T. H., Janreddy, D., \u2026 Hsieh-Li,H. M. (2014). Indole and synthetic derivative activate chaperone expression to reduce polyQ aggregation in SCA17 neuronal cell and slice culture models. Drug Design, Development and Therapy, 8, 1929\u20131939. https:\/\/doi.org\/10.2147\/DDDT.S67376.","DOI":"10.2147\/DDDT.S67376."},{"key":"1981_CR226","doi-asserted-by":"publisher","unstructured":"Rousseaux, M. W. C., Tschumperlin, T., Lu, H. C., Lackey, E. P., Bondar, V. V., Wan,Y. W., \u2026 Orr, H. T. (2018). ATXN1-CIC Complex Is the Primary Driver of Cerebellar Pathology in Spinocerebellar Ataxia Type 1 through a Gain-of-Function Mechanism. Neuron, 97(6), 1235\u20131243.e5. https:\/\/doi.org\/10.1016\/j.neuron.2018.02.013.","DOI":"10.1016\/j.neuron.2018.02.013."},{"key":"1981_CR227","doi-asserted-by":"publisher","unstructured":"Buijsen, R. A. M., Hu, M., S\u00e1ez-Gonz\u00e1lez, M., Notopoulou, S., Mina, E., Koning, W.,\u2026 van Roon-Mom, W. M. C. (2023). Spinocerebellar Ataxia Type 1 Characteristics in Patient-Derived Fibroblast and iPSC-Derived Neuronal Cultures. Movement Disorders, 38(8), 1428\u20131442. https:\/\/doi.org\/10.1002\/mds.29446.","DOI":"10.1002\/mds.29446."},{"key":"1981_CR228","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106673","author":"C Sheeler","year":"2024","unstructured":"Sheeler C, Labrada E, Duvick L, Thompson LM, Zhang Y, Orr HT, et al. Expanded ATXN1 alters transcription and calcium signaling in SCA1 human motor neurons differentiated from induced pluripotent stem cells. Neurobiol Dis. 2024. https:\/\/doi.org\/10.1016\/j.nbd.2024.106673.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"1981_CR229","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12031-012-9930-2","volume":"51","author":"G Xia","year":"2013","unstructured":"Xia G, Santostefano K, Hamazaki T, Liu J, Subramony SH, Terada N, et al. Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro. J Mol Neurosci. 2013;51(2):237\u201348. https:\/\/doi.org\/10.1007\/s12031-012-9930-2.","journal-title":"J Mol Neurosci"},{"issue":"7378","key":"1981_CR230","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature10671","volume":"480","author":"P Koch","year":"2011","unstructured":"Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, Poppe D, et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature. 2011;480(7378):543\u20136. https:\/\/doi.org\/10.1038\/nature10671.","journal-title":"Nature"},{"key":"1981_CR231","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006370","author":"MD Stubenvoll","year":"2016","unstructured":"Stubenvoll MD, Medley JC, Irwin M, Song MH. ATX-2, the C. elegans ortholog of human ataxin-2, regulates centrosome size and microtubule dynamics. PLoS Genet. 2016. https:\/\/doi.org\/10.1371\/journal.pgen.1006370.","journal-title":"PLoS Genet"},{"issue":"12","key":"1981_CR232","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1242\/dmm.029736","volume":"10","author":"Y Fardghassemi","year":"2017","unstructured":"Fardghassemi Y, Tauffenberger A, Gosselin S, Parker JA. Rescue of ATXN3 neuronal toxicity in Caenorhabditis elegans by chemical modification of endoplasmic reticulum stress. DMM Dis Model Mech. 2017;10(12):1465\u201380. https:\/\/doi.org\/10.1242\/dmm.029736.","journal-title":"DMM Dis Model Mech"},{"issue":"2","key":"1981_CR233","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s13311-020-00993-5","volume":"18","author":"Y Fardghassemi","year":"2021","unstructured":"Fardghassemi Y, Maios C, Parker JA. Small molecule rescue of ATXN3 toxicity in C. elegans via TFEB\/HLH-30. Neurotherapeutics. 2021;18(2):1151\u201365. https:\/\/doi.org\/10.1007\/s13311-020-00993-5.","journal-title":"Neurotherapeutics"},{"key":"1981_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113544","author":"Y Fardghassemi","year":"2021","unstructured":"Fardghassemi Y, Parker JA. Overexpression of FKH-2\/FOXG1 is neuroprotective in a C. elegans model of Machado-Joseph disease. Exp Neurol. 2021. https:\/\/doi.org\/10.1016\/j.expneurol.2020.113544.","journal-title":"Exp Neurol"},{"issue":"15","key":"1981_CR235","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1093\/hmg\/ddr203","volume":"20","author":"A Teixeira-Castro","year":"2011","unstructured":"Teixeira-Castro A, Ailion M, Jalles A, Brignull HR, Vilac\u00e3 JL, Dias N, et al. Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Hum Mol Genet. 2011;20(15):2996\u20133009. https:\/\/doi.org\/10.1093\/hmg\/ddr203.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"1981_CR236","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1371\/journal.pgen.0030234","volume":"3","author":"I Al-Ramahi","year":"2007","unstructured":"Al-Ramahi I, P\u00e9rez AM, Lim J, Zhang M, Sorensen R, De Haro M, et al. dAtaxin-2 mediates expanded ataxin-1-induced neurodegeneration in a Drosophila model of SCA1. PLoS Genet. 2007;3(12):2551\u201364. https:\/\/doi.org\/10.1371\/journal.pgen.0030234.","journal-title":"PLoS Genet"},{"issue":"19","key":"1981_CR237","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/hmg\/ddab148","volume":"30","author":"L McGurk","year":"2021","unstructured":"McGurk L, Rifai OM, Shcherbakova O, Perlegos AE, Byrns CN, Carranza FR, et al. Toxicity of pathogenic ataxin-2 in Drosophila shows dependence on a pure CAG repeat sequence. Hum Mol Genet. 2021;30(19):1797\u2013810. https:\/\/doi.org\/10.1093\/hmg\/ddab148.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"1981_CR238","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molcel.2005.02.030","volume":"18","author":"JM Warrick","year":"2005","unstructured":"Warrick JM, Morabito LM, Bilen J, Gordesky-Gold B, Faust LZ, Paulson HL, et al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell. 2005;18(1):37\u201348. https:\/\/doi.org\/10.1016\/j.molcel.2005.02.030.","journal-title":"Mol Cell"},{"issue":"7198","key":"1981_CR239","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/nature06909","volume":"453","author":"L-B Li","year":"2008","unstructured":"Li L-B, Yu Z, Teng X, Bonini NM. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature. 2008;453(7198):1107\u201311. https:\/\/doi.org\/10.1038\/nature06909.","journal-title":"Nature"},{"key":"1981_CR240","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104535","author":"SL Johnson","year":"2019","unstructured":"Johnson SL, Blount JR, Libohova K, Ranxhi B, Paulson HL, Tsou WL, et al. Differential toxicity of ataxin-3 isoforms in Drosophila models of Spinocerebellar Ataxia Type 3. Neurobiol Dis. 2019. https:\/\/doi.org\/10.1016\/j.nbd.2019.104535.","journal-title":"Neurobiol Dis"},{"key":"1981_CR241","doi-asserted-by":"publisher","unstructured":"Johnson, S. L., Prifti, M. V., Sujkowski, A., Libohova, K., Blount, J. R., Hong,L., \u2026 Todi, S. V. (2022). Drosophila as a Model of Unconventional Translation in Spinocerebellar Ataxia Type 3. Cells, 11(7). https:\/\/doi.org\/10.3390\/cells11071223.","DOI":"10.3390\/cells11071223."},{"issue":"15","key":"1981_CR242","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1093\/hmg\/ddv174","volume":"24","author":"WL Tsou","year":"2015","unstructured":"Tsou WL, Hosking RR, Burr AA, Sutton JR, Ouyang M, Du X, et al. DnaJ-1 and karyopherin \u03b13 suppress degeneration in a new Drosophila model of Spinocerebellar Ataxia Type 6. Hum Mol Genet. 2015;24(15):4385\u201396. https:\/\/doi.org\/10.1093\/hmg\/ddv174.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"1981_CR243","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1242\/bio.021667","volume":"5","author":"WL Tsou","year":"2016","unstructured":"Tsou WL, Qiblawi SH, Hosking RR, Gomez CM, Todi SV. Polyglutamine length-dependent toxicity from \u03b11ACT in Drosophila models of spinocerebellar ataxia type 6. Biol Open. 2016;5(12):1770\u20135. https:\/\/doi.org\/10.1242\/bio.021667.","journal-title":"Biol Open"},{"key":"1981_CR244","doi-asserted-by":"publisher","unstructured":"Nath, S., Caron, N. S., May, L., Gluscencova, O. B., Kolesar, J., Brady, L., \u2026 Truant,R. (2022). Functional characterization of variants of unknown significance in a spinocerebellar ataxia patient using an unsupervised machine learning pipeline. Human Genome Variation, 9(1). https:\/\/doi.org\/10.1038\/s41439-022-00188-8.","DOI":"10.1038\/s41439-022-00188-8."},{"key":"1981_CR245","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147351","author":"MA Elsaey","year":"2021","unstructured":"Elsaey MA, Namikawa K, K\u00f6ster RW. Genetic modeling of the neurodegenerative disease spinocerebellar ataxia type 1 in Zebrafish. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22147351.","journal-title":"Int J Mol Sci"},{"key":"1981_CR246","doi-asserted-by":"publisher","unstructured":"Sellier, C., Campanari, M., Julie Corbier, C., Gaucherot, A., Kolb-Cheynel, I., Oulad\u2010Abdelghani,M., \u2026 Charlet\u2010Berguerand, N. (2016). Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin\u20102 to induce motor neuron dysfunction and cell death. The EMBO Journal, 35(12), 1276\u20131297. https:\/\/doi.org\/10.15252\/embj.201593350.","DOI":"10.15252\/embj.201593350."},{"issue":"32","key":"1981_CR247","doi-asserted-by":"publisher","first-page":"7782","DOI":"10.1523\/JNEUROSCI.1142-17.2017","volume":"37","author":"M Watchon","year":"2017","unstructured":"Watchon M, Yuan KC, Mackovski N, Svahn AJ, Cole NJ, Goldsbury C, et al. Calpain inhibition is protective in machado\u2013joseph disease zebrafish due to induction of autophagy. J Neurosci. 2017;37(32):7782\u201394. https:\/\/doi.org\/10.1523\/JNEUROSCI.1142-17.2017.","journal-title":"J Neurosci"},{"issue":"4","key":"1981_CR248","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cell.2006.09.036","volume":"127","author":"HG Serra","year":"2006","unstructured":"Serra HG, Duvick L, Zu T, Carlson K, Stevens S, Jorgensen N, et al. ROR\u03b1-mediated Purkinje cell development determines disease severity in adult SCA1 Mice. Cell. 2006;127(4):697\u2013708. https:\/\/doi.org\/10.1016\/j.cell.2006.09.036.","journal-title":"Cell"},{"key":"1981_CR249","doi-asserted-by":"publisher","unstructured":"Watase, K., Weeber, E. J., Xu, B., Antalffy, B., Yuva-Paylor, L., Hashimoto, K.,\u2026 Zoghbi, H. Y. (2002). A Long CAG Repeat in the Mouse Sca1 Locus Replicates SCA1 Features and Reveals the Impact of Protein Solubility on Selective Neurodegeneration.Neuron, 34(6), 905\u2013919. https:\/\/doi.org\/10.1016\/S0896-6273(02)00733-X.","DOI":"10.1016\/S0896-6273(02)00733-X."},{"key":"1981_CR250","doi-asserted-by":"publisher","unstructured":"Luttik, K., Tejwani, L., Ju, H., Driessen, T., Smeets, C. J. L. M., Reddy Edamakanti,C., \u2026 Lim, J. (2022). Differential effects of Wnt-\u03b2-catenin signaling in Purkinje cells and Bergmann glia in spinocerebellar ataxia type 1. https:\/\/doi.org\/10.1073\/pnas.","DOI":"10.1073\/pnas."},{"issue":"20","key":"1981_CR251","doi-asserted-by":"publisher","DOI":"10.3390\/cells11203323","volume":"11","author":"J-G Rosa","year":"2022","unstructured":"Rosa J-G, Hamel K, Sheeler C, Borgenheimer E, Gilliat S, Soles A, et al. Spatial and temporal diversity of astrocyte phenotypes in spinocerebellar ataxia type 1 Mice. Cells. 2022;11(20):3323. https:\/\/doi.org\/10.3390\/cells11203323.","journal-title":"Cells"},{"key":"1981_CR252","doi-asserted-by":"publisher","unstructured":"Orengo JP, Nitschke L, van der Heijden ME, Ciaburri NA, Orr HT, Zoghbi HY, Neurological D, Research D, O U R C E A N D T E C H N I C A L A D V. A N C E Reduction of mutant ATXN1 rescues premature death in a conditional SCA1 mouse model. Ref information: JCI Insight, 7(8). https:\/\/doi.org\/10.1172\/jci.","DOI":"10.1172\/jci"},{"issue":"5","key":"1981_CR253","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/jnc.12435","volume":"127","author":"UE Emir","year":"2013","unstructured":"Emir UE, Brent Clark H, Vollmers ML, Eberly LE, \u00d6z G. Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1. J Neurochem. 2013;127(5):660\u20138. https:\/\/doi.org\/10.1111\/jnc.12435.","journal-title":"J Neurochem"},{"issue":"1","key":"1981_CR254","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/hmg\/ddz265","volume":"29","author":"M Asher","year":"2020","unstructured":"Asher M, Rosa J-G, Rainwater O, Duvick L, Bennyworth M, Lai R-Y, et al. Cerebellar contribution to the cognitive alterations in SCA1: evidence from mouse models. Hum Mol Genet. 2020;29(1):117\u201331. https:\/\/doi.org\/10.1093\/hmg\/ddz265.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"1981_CR255","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80664-9","volume":"11","author":"M Asher","year":"2021","unstructured":"Asher M, Rosa J-G, Cvetanovic M. Mood alterations in mouse models of spinocerebellar ataxia type 1. Sci Rep. 2021;11(1):713. https:\/\/doi.org\/10.1038\/s41598-020-80664-9.","journal-title":"Sci Rep"},{"issue":"1","key":"1981_CR256","doi-asserted-by":"publisher","first-page":"78","DOI":"10.15252\/emmm.201404392","volume":"7","author":"H Ito","year":"2015","unstructured":"Ito H, Fujita K, Tagawa K, Chen X, Homma H, Sasabe T, et al. HMGB1 facilitates repair of mitochondrial DNA damage and extends the lifespan of mutant ataxin-1 knock\u2010in mice. EMBO Mol Med. 2015;7(1):78\u2013101. https:\/\/doi.org\/10.15252\/emmm.201404392.","journal-title":"EMBO Mol Med"},{"issue":"5","key":"1981_CR257","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/hmg\/9.5.779","volume":"9","author":"D Lorenzetti","year":"2000","unstructured":"Lorenzetti D. Repeat instability and motor incoordination in mice with a targeted expanded CAG repeat in the Sca1 locus. Hum Mol Genet. 2000;9(5):779\u201385. https:\/\/doi.org\/10.1093\/hmg\/9.5.779.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"1981_CR258","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/79162","volume":"26","author":"DP Huynh","year":"2000","unstructured":"Huynh DP, Figueroa K, Hoang N, Pulst S-M. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet. 2000;26(1):44\u201350. https:\/\/doi.org\/10.1038\/79162.","journal-title":"Nat Genet"},{"key":"1981_CR259","doi-asserted-by":"publisher","unstructured":"Huynh, D. P., Maalouf, M., Silva, A. J., Schweizer, F. E., & Pulst, S. M. (2009).Dissociated fear and spatial learning in mice with deficiency of ataxin-2. PLoS ONE, 4(7). https:\/\/doi.org\/10.1371\/journal.pone.0006235.","DOI":"10.1371\/journal.pone.0006235."},{"key":"1981_CR260","doi-asserted-by":"publisher","unstructured":"Dansithong, W., Paul, S., Figueroa, K. P., Rinehart, M. D., Wiest, S., Pflieger,L. T., \u2026 Pulst, S. M. (2015). Ataxin-2 Regulates RGS8 Translation in a New BAC-SCA2 Transgenic Mouse Model. PLoS Genetics, 11(4). https:\/\/doi.org\/10.1371\/journal.pgen.1005182.","DOI":"10.1371\/journal.pgen.1005182."},{"key":"1981_CR261","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104559","volume":"132","author":"N-E Sen","year":"2019","unstructured":"Sen N-E, Canet-Pons J, Halbach MV, Arsovic A, Pilatus U, Chae W-H, et al. Generation of an Atxn2-CAG100 knock-in mouse reveals N-acetylaspartate production deficit due to early Nat8l dysregulation. Neurobiol Dis. 2019;132:104559. https:\/\/doi.org\/10.1016\/j.nbd.2019.104559.","journal-title":"Neurobiol Dis"},{"issue":"18","key":"1981_CR262","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21186673","volume":"21","author":"A Arsovi\u0107","year":"2020","unstructured":"Arsovi\u0107 A, Halbach MV, Canet-Pons J, Esen-Sehir D, D\u00f6ring C, Freudenberg F, et al. Mouse ataxin-2 expansion downregulates camkii and other calcium signaling factors, impairing granule\u2014purkinje neuron synaptic strength. Int J Mol Sci. 2020;21(18):1\u201336. https:\/\/doi.org\/10.3390\/ijms21186673.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"1981_CR263","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1093\/hmg\/ddx224","volume":"26","author":"B Ramani","year":"2017","unstructured":"Ramani B, Panwar B, Moore LR, Wang B, Huang R, Guan Y, et al. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes. Hum Mol Genet. 2017;26(17):3362\u201374. https:\/\/doi.org\/10.1093\/hmg\/ddx224.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"1981_CR264","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13311-013-0255-9","volume":"11","author":"A Silva-Fernandes","year":"2014","unstructured":"Silva-Fernandes A, Duarte-Silva S, Neves-Carvalho A, Amorim M, Soares-Cunha C, Oliveira P, et al. Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease. Neurotherapeutics. 2014;11(2):433\u201349. https:\/\/doi.org\/10.1007\/s13311-013-0255-9.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"1981_CR265","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.nbd.2009.08.002","volume":"37","author":"J Boy","year":"2010","unstructured":"Boy J, Schmidt T, Schumann U, Grasshoff U, Unser S, Holzmann C, et al. A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats. Neurobiol Dis. 2010;37(2):284\u201393. https:\/\/doi.org\/10.1016\/j.nbd.2009.08.002.","journal-title":"Neurobiol Dis"},{"key":"1981_CR266","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193132","author":"ME Tsimpanouli","year":"2022","unstructured":"Tsimpanouli ME, Ghimire A, Barget AJ, Weston R, Paulson HL, Costa M, et al. Sleep alterations in a mouse model of spinocerebellar ataxia type 3. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11193132.","journal-title":"Cells"},{"issue":"45","key":"1981_CR267","doi-asserted-by":"publisher","first-page":"10266","DOI":"10.1523\/JNEUROSCI.2734-04.2004","volume":"24","author":"D Goti","year":"2004","unstructured":"Goti D, Katzen SM, Mez J, Kurtis N, Kiluk J, Ben-Ha\u00efem L, et al. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci. 2004;24(45):10266\u201379. https:\/\/doi.org\/10.1523\/JNEUROSCI.2734-04.2004.","journal-title":"J Neurosci"},{"issue":"3","key":"1981_CR268","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.bbrc.2007.08.062","volume":"362","author":"I Schmitt","year":"2007","unstructured":"Schmitt I, Linden M, Khazneh H, Evert BO, Breuer P, Klockgether T, et al. Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem Biophys Res Commun. 2007;362(3):734\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2007.08.062.","journal-title":"Biochem Biophys Res Commun"},{"issue":"28","key":"1981_CR269","doi-asserted-by":"publisher","first-page":"7418","DOI":"10.1523\/JNEUROSCI.4540-06.2007","volume":"27","author":"U Bichelmeier","year":"2007","unstructured":"Bichelmeier U, Schmidt T, H\u00fcbener J, Boy J, R\u00fcttiger L, H\u00e4big K, et al. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: In vivo evidence. J Neurosci. 2007;27(28):7418\u201328. https:\/\/doi.org\/10.1523\/JNEUROSCI.4540-06.2007.","journal-title":"J Neurosci"},{"issue":"1","key":"1981_CR270","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.nbd.2008.03.011","volume":"31","author":"AH Chou","year":"2008","unstructured":"Chou AH, Yeh TH, Ouyang P, Chen YL, Chen SY, Wang HL. Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol Dis. 2008;31(1):89\u2013101. https:\/\/doi.org\/10.1016\/j.nbd.2008.03.011.","journal-title":"Neurobiol Dis"},{"issue":"22","key":"1981_CR271","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1093\/hmg\/ddp381","volume":"18","author":"J Boy","year":"2009","unstructured":"Boy J, Schmidt T, Wolburg H, Mack A, Nuber S, B\u00f6ttcher M, et al. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Hum Mol Genet. 2009;18(22):4282\u201395. https:\/\/doi.org\/10.1093\/hmg\/ddp381.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"1981_CR272","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.nbd.2010.05.021","volume":"40","author":"A Silva-Fernandes","year":"2010","unstructured":"Silva-Fernandes A, Costa M, Duarte-Silva S, Oliveira P, Botelho CM, Martins L, et al. Motor uncoordination and neuropathology in a transgenic mouse model of Machado\u2013Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Neurobiol Dis. 2010;40(1):163\u201376. https:\/\/doi.org\/10.1016\/j.nbd.2010.05.021.","journal-title":"Neurobiol Dis"},{"key":"1981_CR273","doi-asserted-by":"publisher","unstructured":"Wiatr, K., Marczak, \u0141., P\u00e9rot, J.-B., Brouillet, E., Flament, J., & Figiel, M. (2021).Broad Influence of Mutant Ataxin-3 on the Proteome of the Adult Brain, Young Neurons,and Axons Reveals Central Molecular Processes and Biomarkers in SCA3\/MJD Using Knock-In Mouse Model. Frontiers in Molecular Neuroscience, 14. https:\/\/doi.org\/10.3389\/fnmol.2021.658339.","DOI":"10.3389\/fnmol.2021.658339."},{"key":"1981_CR274","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez-Cueto, C., Hern\u00e1ndez-G\u00e1lvez, M., Hillard, C. J., Maciel, P., Garc\u00eda-Garc\u00eda,L., Valdeolivas, S., \u2026 Fern\u00e1ndez-Ruiz, J. (2016). Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3. Neuroscience, 339, 191\u2013209. https:\/\/doi.org\/10.1016\/j.neuroscience.2016.09.046.","DOI":"10.1016\/j.neuroscience.2016.09.046."},{"issue":"22","key":"1981_CR275","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1093\/hmg\/ddac135","volume":"31","author":"P Bohne","year":"2022","unstructured":"Bohne P, Rybarski M, Mourabit DBE, Krause F, Mark MD. Cerebellar contribution to threat probability in a SCA6 mouse model. Hum Mol Genet. 2022;31(22):3807\u201328. https:\/\/doi.org\/10.1093\/hmg\/ddac135.","journal-title":"Hum Mol Genet"},{"key":"1981_CR276","doi-asserted-by":"publisher","unstructured":"Yvert, G., Lindenberg, K. S., Picaud, S., Landwehrmeyer, G. B., Sahel, J. A., & Mandel,J. L. (2000). Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Human Molecular Genetics, 9(17), 2491\u20132506. https:\/\/doi.org\/10.1093\/hmg\/9.17.2491.","DOI":"10.1093\/hmg\/9.17.2491."},{"key":"1981_CR277","doi-asserted-by":"publisher","unstructured":"La Spada, A. R., Fu, Y.-H., Sopher, B. L., Libby, R. T., Wang, X., Li, L. Y., \u2026 Chen,S. (2001). Polyglutamine-Expanded Ataxin-7 Antagonizes CRX Function and Induces Cone-Rod Dystrophy in a Mouse Model of SCA7. Neuron, 31(6), 913\u2013927. https:\/\/doi.org\/10.1016\/S0896-6273(01)00422-6.","DOI":"10.1016\/S0896-6273(01)00422-6."},{"key":"1981_CR278","doi-asserted-by":"publisher","unstructured":"Libby, R. T., Monckton, D. G., Fu, Y. H., Martinez, R. A., McAbney, J. P., Lau, R.,\u2026 La Spada, A. R. (2003). Genomic context drives SCA7 CAG repeat instability, while expressed SCA7 cDNAs are intergenerationally and somatically stable in transgenic mice. Human Molecular Genetics, 12(1), 41\u201350. https:\/\/doi.org\/10.1093\/hmg\/ddg006.","DOI":"10.1093\/hmg\/ddg006."},{"key":"1981_CR279","doi-asserted-by":"publisher","unstructured":"Yoo, S.-Y., Pennesi, M. E., Weeber, E. J., Xu, B., Atkinson, R., Chen, S., \u2026 Zoghbi,H. Y. (2003). SCA7 Knockin Mice Model Human SCA7 and Reveal Gradual Accumulation of Mutant Ataxin-7 in Neurons and Abnormalities in Short-Term Plasticity. Neuron, 37(3), 383\u2013401. https:\/\/doi.org\/10.1016\/S0896-6273(02)01190-X.","DOI":"10.1016\/S0896-6273(02)01190-X."},{"key":"1981_CR280","doi-asserted-by":"publisher","unstructured":"Alves, S., Cormier-Dequaire, F., Marinello, M., Marais, T., Muriel, M. P., Beaumatin,F., \u2026 Sittler, A. (2014). The autophagy\/lysosome pathway is impaired in SCA7 patients and SCA7 knock-in mice. Acta Neuropathologica, 128(5), 705\u2013722. https:\/\/doi.org\/10.1007\/s00401-014-1289-8.","DOI":"10.1007\/s00401-014-1289-8."},{"key":"1981_CR281","doi-asserted-by":"crossref","unstructured":"Fusco, A. F., Pucci, L. A., Switonski, P. M., Biswas, D. D., McCall, A. L., Kahn,A. F., & ElMallah, M. K. (2021). Respiratory dysfunction in a mouse model of spinocerebellar ataxia type 7. Disease Models & Mechanisms.","DOI":"10.1242\/dmm.048893"},{"key":"1981_CR282","doi-asserted-by":"publisher","unstructured":"Chang, Y., Lin, C., Hsu, C., Lin, H., Chen, Y., Lee-Chen, G., \u2026 Hsieh\u2010Li, H. M. (2011).Neuroprotective effects of granulocyte\u2010colony stimulating factor in a novel transgenic mouse model of SCA17. Journal of Neurochemistry, 118(2), 288\u2013303. https:\/\/doi.org\/10.1111\/j.1471-4159.2011.07304.x.","DOI":"10.1111\/j.1471-4159.2011.07304.x."},{"issue":"4","key":"1981_CR283","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s12311-020-01127-5","volume":"19","author":"C-C Chen","year":"2020","unstructured":"Chen C-C, Yao N-W, Lin C-W, Su W-S, Wu C-T, Chang C, et al. Neuroimaging spectrum at pre-, early, and late symptomatic stages of SCA17 mice. Cerebellum. 2020;19(4):487\u2013500. https:\/\/doi.org\/10.1007\/s12311-020-01127-5.","journal-title":"Cerebellum"},{"key":"1981_CR284","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.135337","volume":"738","author":"C-W Lin","year":"2020","unstructured":"Lin C-W, Fan C-H, Chang Y-C, Hsieh-Li HM. ERK activation precedes Purkinje cell loss in mice with Spinocerebellar ataxia type 17. Neurosci Lett. 2020;738:135337. https:\/\/doi.org\/10.1016\/j.neulet.2020.135337.","journal-title":"Neurosci Lett"},{"issue":"1","key":"1981_CR285","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.celrep.2015.08.060","volume":"13","author":"S Huang","year":"2015","unstructured":"Huang S, Yang S, Guo J, Yan S, Gaertig MA, Li S, et al. Large polyglutamine repeats cause muscle degeneration in SCA17 mice. Cell Rep. 2015;13(1):196\u2013208. https:\/\/doi.org\/10.1016\/j.celrep.2015.08.060.","journal-title":"Cell Rep"},{"issue":"2","key":"1981_CR286","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.neuron.2013.12.002","volume":"81","author":"S Yang","year":"2014","unstructured":"Yang S, Huang S, Gaertig MA, Li X-J, Li S. Age-dependent decrease in chaperone activity impairs MANF expression, leading to Purkinje cell degeneration in inducible SCA17 mice. Neuron. 2014;81(2):349\u201365. https:\/\/doi.org\/10.1016\/j.neuron.2013.12.002.","journal-title":"Neuron"},{"key":"1981_CR287","doi-asserted-by":"publisher","unstructured":"Tomioka, I., Nagai, Y., & Seki, K. (2020). Generation of Common Marmoset Model Lines of Spinocerebellar Ataxia Type 3. Frontiers in Neuroscience, 14. https:\/\/doi.org\/10.3389\/fnins.2020.548002.","DOI":"10.3389\/fnins.2020.548002."},{"key":"1981_CR288","doi-asserted-by":"publisher","unstructured":"Minakawa, E. N., Owari, K., Nogami, N., Nakatani, T., Koizumi, M., Kawanobe, A.,\u2026 Seki, K. (2025). Establishment of a second-generation transgenic marmoset with germline transmission that models polyglutamine disease. Disease Models & Mechanisms, 18(10). https:\/\/doi.org\/10.1242\/dmm.052470.","DOI":"10.1242\/dmm.052470."},{"key":"1981_CR289","doi-asserted-by":"publisher","unstructured":"Henriques, C., Lobo, D. D., Silva, A. C., Fernandes, A. R., Lopes, M. M., Fayard,A., \u2026 Nobre, R. J. (2025, October 2). AAV-mediated allele-specific silencing alleviates neuropathology in a novel non-human primate model of Spinocerebellar ataxia type 3.https:\/\/doi.org\/10.1101\/2025.10.02.680027.","DOI":"10.1101\/2025.10.02.680027."}],"container-title":["The Cerebellum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-026-01981-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-026-01981-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-026-01981-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:06:37Z","timestamp":1776686797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12311-026-01981-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":289,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1981"],"URL":"https:\/\/doi.org\/10.1007\/s12311-026-01981-9","relation":{},"ISSN":["1473-4230"],"issn-type":[{"value":"1473-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}